# THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE

# CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

convenes the

FORTY-FIRST MEETING

ADVISORY BOARD ON

RADIATION AND WORKER HEALTH

### ABRWH BOARD MEETING

The verbatim transcript of the

Meeting of the Advisory Board on Radiation and

Worker Health held telephonically on October 18,

2006.

# C O N T E N T S

October 18, 2006

Ι	DR. PAUL ZIEMER, CHAIR DR. LEWIS WADE, DFO	,
H H	ASSIGNMENT OF BOARD MEMBER REVIEW TEAMS FOR THE 6 <sup>TH</sup> ROUND OF INDIVIDUAL DOSE RECONSTRUCTION REVIEWS (AND REASSIGNMENT OF SOME 5 <sup>TH</sup> ROUND CASES RESULTING FROM THE RETIREMENT OF DR. DEHART) DR. ZIEMER, CHAIR	10
Ç	CONFLICT OF INTEREST UPDATE CONCERNING THE SC&A CONTRACT	24
Ε	WORKING GROUP (WG) REPORTS AND SCHEDULING FOR FUTURE WORK GROUP MEETINGS WG CHAIRS	41
	BOARD WORKING TIME: DR. ZIEMER, CHAIR	
	DISCUSSION OF SITE PROFILE REVIEW TASK FOR SC&A IN FY07	92
	NEED FOR NEW WORKING GROUPS (I.E. PROCEDURES REVIEW)	95
	DISCUSSION OF WORKING GROUP & SUBCOMMITTEE MEETING DURING THE DECEMBER FACE-TO-FACE MEETING	102
(	COURT REPORTER'S CERTIFICATE	112

#### TRANSCRIPT LEGEND

The following transcript contains quoted material. Such material is reproduced as read or spoken.

In the following transcript: a dash (--) indicates an unintentional or purposeful interruption of a sentence. An ellipsis (. . .) indicates halting speech or an unfinished sentence in dialogue or omission(s) of word(s) when reading written material.

- -- (sic) denotes an incorrect usage or pronunciation of a word which is transcribed in its original form as reported.
- -- (phonetically) indicates a phonetic spelling of the word if no confirmation of the correct spelling is available.
- -- "uh-huh" represents an affirmative response, and "uh-uh" represents a negative response.
- -- "\*" denotes a spelling based on phonetics, without reference available.
- -- (inaudible)/ (unintelligible) signifies speaker failure, usually failure to use a microphone.

### PARTICIPANTS

(By Group, in Alphabetical Order)

#### BOARD MEMBERS

#### CHAIR

ZIEMER, Paul L., Ph.D.
Professor Emeritus
School of Health Sciences
Purdue University
Lafayette, Indiana

#### EXECUTIVE SECRETARY

WADE, Lewis, Ph.D.
Senior Science Advisor
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
Washington, DC

#### MEMBERSHIP

CLAWSON, Bradley
Senior Operator, Nuclear Fuel Handling
Idaho National Engineering & Environmental Laboratory

GIBSON, Michael H.

President

Paper, Allied-Industrial, Chemical, and Energy Union Local 5-4200 Miamisburg, Ohio

GRIFFON, Mark A.

President

Creative Pollution Solutions, Inc.

Salem, New Hampshire

LOCKEY, James, M.D.

Professor, Department of Environmental Health College of Medicine, University of Cincinnati MELIUS, James Malcom, M.D., Ph.D.
Director
New York State Laborers' Health and Safety Trust Fund
Albany, New York

MUNN, Wanda I. Senior Nuclear Engineer (Retired) Richland, Washington

PRESLEY, Robert W. Special Projects Engineer BWXT Y12 National Security Complex Clinton, Tennessee

ROESSLER, Genevieve S., Ph.D. Professor Emeritus University of Florida Elysian, Minnesota

## ANNOUNCED PARTICIPANTS

BEHLING, KATHY, SC&A
ELLIOTT, LARRY, NIOSH
ESCOBAR, FELICIA, SEN. SALAZAR
FITZGERALD, JOE, SC&A
HINNEFELD, STUART, NIOSH
HOWELL, EMILY, HHS
MAURO, JOHN, SC&A
NETON, JIM, NIOSH
STAUDT, DAVID, CDC
ULSH, BRANT, NIOSH

## PROCEEDINGS

(10:00 a.m.)

# WELCOME AND OPENING COMMENTS DR. PAUL ZIEMER, CHAIR

1	DR. ZIEMER: Okay, Ray is now with us
2	DR. WADE: I see.
3	DR. ZIEMER: and ready to go, so maybe
4	maybe we should call the meeting to order.
5	DR. WADE: Mark, are you with us?
6	MR. GRIFFON: Yes, I'm here.
7	DR. ZIEMER: Ah, good, Mark.
8	DR. WADE: Okay. And Ray, are you ready to
9	begin?
10	THE COURT REPORTER: Yes, sir.
11	DR. ZIEMER: So I will call the meeting to
12	order. This is the conference call meeting of
13	the Advisory Board on Radiation and Worker
14	Health. This is those present are Ziemer,
15	Lockey, Munn, Roessler, Presley, Gibson,
16	Clawson, Melius, Griffon and Lew Wade, the
17	Designated Federal Official. Dr. Poston is
18	unable to be with us today.
19	We also have a number of staff people here. We
20	don't need to identify them all at the moment -

1	- or do we? Do we need that for the record,
2	Dr. Wade?
3	DR. WADE: No, I don't know that we do. I
4	think if anyone is going to participate in the
5	discussion, they need to
6	DR. ZIEMER: Yeah, they can
7	DR. WADE: clearly identify themself.
8	DR. ZIEMER: identify as they participate.
9	Also there may be members of the public on the
10	phone lines as well.
11	DR. WADE: I would ask if there are any
12	representatives of members of Congress who
13	would like to be identified on the call.
14	MS. ESCOBAR: This is Felicia Escobar. I work
15	for Senator Ken Salazar and
16	DR. ZIEMER: Oh, thank you.
17	MS. ESCOBAR: Uh-huh.
18	DR. ZIEMER: And Ray, did you get that?
19	THE COURT REPORTER: I believe so, Felicia
20	Escobar?
21	MS. ESCOBAR: Yes.
22	THE COURT REPORTER: Okay. Thank you.
23	MS. ESCOBAR: Uh-huh.
24	DR. WADE: Anyone else who would like to be
25	identified?

1

#### (No responses)

23

24

25

DR. ZIEMER: Very good. Let me then welcome everybody to the conference call. I'll make a few preliminary remarks and then Dr. Wade will also have an opportunity to make some additional remarks.

I hope all of you have a copy of the agenda, and we are blocked off time-wise to go till 1:30. It's not mandatory that we go to 1:30. Our items of -- of deliberation are all items that are more in the form of reports and updates, and therefore we may be able to have a more streamlined meeting, although it's not mandatory that we -- that we make it shorter, either. The designated time frames have been set aside based on estimates and, as you know, we will proceed with the agenda as we complete items, so that the time frame that was disseminated may not necessarily be the final time frame that we end up with. So with the understanding that we have that flexibility to move ahead as we complete items, why we will proceed. I thank every for participating. Lew, you have some additional remarks?

DR. WADE: Only to thank everyone for their

1 participation and also, you know, the modus 2 operandi we've sort of evolved into is that 3 between Board meetings we schedule -- between 4 face-to-face Board meetings we schedule a 5 telephone call. And again, it's really to sort of wrap up loose ends and deal with issues that 6 7 need to be dealt with before we sit down 8 together again. And you know, at some points 9 that -- the demands will be greater than 10 others. As Paul said, I don't know that we'll 11 use the entire day today, but I do think it's a good idea to have these calls scheduled and to 12 13 deal with issues because, as you'll see today, 14 there are several issues that really wouldn't -15 - would best not wait until we're next together 16 in December. And that's the purpose of the 17 call, so I appreciate your discipline, those of 18 you who were with us in making these calls, and 19 I appreciate your efforts.

ASSIGNMENT OF BOARD MEMBER REVIEW TEAMS FOR THE  $6^{\text{TH}}$  ROUND OF INDIVIDUAL DOSE RECONSTRUCTION REVIEWS (AND REASSIGNMENT OF SOME  $5^{\text{TH}}$  ROUND CASES RESULTING FROM THE RETIREMENT OF DR. DEHART)

20

21

22

23

DR. ZIEMER: Well, let's go to the first item on the agenda, which deals with the dose reconstruction review process. And I'd like to look first at round five. And you may recall

1 that round five, we had -- had assigned all the 2 teams for that. And to the best of my 3 knowledge, all of those teams have completed 4 their interactions with the SC&A staff. And 5 Kathy and Hans, can you confirm that that is the case? 6 7 MS. BEHLING: Yes, we have one more team to go 8 through the -- the cases, but everyone else is 9 complete at this point. 10 DR. ZIEMER: Okay. And I should point out --11 and I don't know if you all have a copy of the 12 -- the cases and the teams that -- I think a 13 copy was disseminated within the last couple of 14 weeks, but the first team on that list was 15 DeHart and Roessler, and DeHart of course --16 his term ended on the Board prior to his 17 actually doing the reviews. My understanding 18 is that Dr. Roessler ended up working without 19 DeHart with the SC&A folks. Gen, is that 20 correct? 21 DR. ROESSLER: That's true, I had to do it on 22 my own. 23 DR. ZIEMER: Well, we thank you for doing that 24 sort of double duty and appreciate the fact 25 'cause that put the whole burden on you to

handle those particular cases. But anyway, we
thank you for that.
So with the exception of whatever single team -
- and you've got that scheduled then, Kathy,
for
MS. BEHLING: Yes, I do. It's scheduled for
tomorrow.
DR. ZIEMER: Oh, okay. So
MS. BEHLING: So we should be finished by
tomorrow.
DR. ZIEMER: So those'll be finished and then I
assume that we will have before our next
meeting then we will have the official draft of
the findings and
MS. BEHLING: Yes.
DR. ZIEMER: and that will be able to start
the matrix process at our meeting in in
December.
MS. BEHLING: That's correct.
DR. ZIEMER: Very good. Let me ask if anyone
has any questions on round five at this point.
has any questions on round five at this point.  (No responses)
(No responses)

1 get a copy of that? It went out within the 2 last couple of weeks. Is anyone lacking a copy 3 of that, the 20 cases for round six? 4 (No responses) 5 Okay. Lew, you have had an opportunity to 6 check conflicts of interest relative to the 7 facilities involved with the round six audit 8 selection, so do you want to share those with 9 us? 10 DR. WADE: Surely. Again what I did was I gave 11 the list to our attorneys and asked them to 12 identify potential conflicts of Board members, 13 and I'll be referring to the selection ID 14 number when I make this report. And I'll only 15 be reporting those situations where a conflict 16 has been raised to my attention. 17 For item 18, selection ID that ends in 18, 18 Griffon and Presley are conflicted. 19 For item 19, Gibson, Griffon and Poston are 20 conflicted. 21 For item 22, Griffon. 22 For item 31, Munn. 23 For item 48, Munn. 24 For item 49, Griffon and Presley. 25 For item 96, Griffon and Presley.

1 For item 106, Clawson and Griffon. 2 For item 144, Munn. 3 For item 163, Munn. 4 For item 166, Griffon, Poston, Presley, Ziemer. 5 And for item 171, Gibson, Griffon. So that's the report I have from the attorneys. 6 Again, I think -- you know, as is always the 7 8 case, we see members with conflicts, but that 9 speaks to the fact that you are valuable 10 additions to the Board. I think that there is 11 a way to work through that now. Dr. Ziemer. 12 DR. ZIEMER: Okay. Thank you. Now I'm -- as a 13 first effort to get the assignments here, I 14 would like to, if we're able to, use the same 15 teams with the following exception. 16 two-person teams except for when we made the 17 last group of assignments we put Dr. Lockey on the team with -- with Mike Gibson and me, so we 18 19 had a three-person team there. But the other 20 teams were two-person teams and then now we 21 have Roessler as a one-person team. So I'm --22 I would propose that we move Lockey to the team 23 to replace DeHart, so Lockey and Roessler would 24 work together if we're able to find suitable --25 suitable cases without conflicts of interest.

1 Would that be agreeable, Gen, and --2 DR. ROESSLER: It's agreeable to me. 3 DR. LOCKEY: Yeah, it's fine with me. 4 DR. ZIEMER: Now that means we have five teams 5 of two, and we have 20 cases, which means each team would have four cases. And I -- I think, 6 and we've found in the past, the easiest way to 7 8 do this is to start out with team one and find 9 four cases for them and then on to team two and 10 Then we would take them in order, 11 unless there's a conflict. 12 So for example, the Roessler/Lockey team -- and we may have to trade some if this doesn't work 13 14 out, but Roessler/Lockey could take cases --15 let me just propose this and if -- and we'll 16 just go down through the list and then see if -17 - if it's agreeable -- would take cases 8, 18 and 19 and 20, and --18 19 DR. ROESSLER: On here it's 22. 20 DR. WADE: It's 22, Paul. 21 DR. ZIEMER: I'm sorry, 22. 22 Okay. DR. ROESSLER: 23 DR. ZIEMER: Correct. I just read it wrong. 24 And there would be no conflict there. 25 Then Presley/Poston would take cases 26, 20 --

1 31, 33 and 48. Now I'm going to skip the 2 Griffon team for the moment because there's a 3 bunch of Griffon ones here, and we go to the 4 Gibson/Ziemer team, and they would take 93, 96, 5 106 and 1-- get this right, I'm sorry -- 49, 93, 96 and 106. Did I get those right? 6 7 DR. WADE: Correct. 8 DR. ZIEMER: Yeah. Then Griffon/Clawson could 9 take 113, 125, 136 and 144. Now we're going to 10 run into a problem here I see, so we're going 11 to have to do a trade in a minute 'cause -- but 12 let me do Munn/Melius. Let's -- let's skip 163 13 for a moment and put Munn/Melius on 166, 171 14 and 181, and then do a trade and bring -- do a 15 trade -- 163, let's put Roessler and Lockey in 16 there and -- and put Melius/Munn on 008 at the 17 top. 18 DR. ROESSLER: Okay, so we get the Hanford, 19 163. DR. ZIEMER: 20 Right. 21 DR. ROESSLER: Okay. DR. ZIEMER: Now I -- I think -- I think with 22 23 that arrangement -- I think we have -- we've 24 used all the teams. Right? Five teams of two, 25 and I think we have no conflicts.

1	DR. LOCKEY: So we have five cases then?
2	DR. ZIEMER: No, four.
3	DR. LOCKEY: Which one did you take away from -
4	- I missed that.
5	DR. ROESSLER: Number 8.
6	DR. LOCKEY: Number 8, okay.
7	DR. ZIEMER: I took number 8 away from you.
8	We'll give that to to Melius/Munn. We're
9	just trading that one since they have a
10	conflict on that
11	DR. LOCKEY: Gotcha, that's
12	DR. ZIEMER: that one. That would that
13	would give everybody their four cases without
14	conflict.
15	DR. ROESSLER: Ray, can you do you recognize
16	the voices, or should we identify ourselves?
17	This is Gen.
18	(No response)
19	Ray's not there.
20	DR. WADE: Ray, are you with us?
21	(No response)
22	Ray?
23	DR. ROESSLER: Uh-oh.
24	MR. GRIFFON: He's taping it and he's taking a
25	nap.

1	DR. WADE: I will make a call.
2	DR. ZIEMER: We'll stand by for a minute.
3	Maybe we lost Ray along the line here.
4	DR. LOCKEY: See, this is he didn't get the
5	gold medal.
6	DR. ZIEMER: I wonder where what we lost
7	Ray.
8	THE COURT REPORTER: Dr. Ziemer, I'm here.
9	This phone can you hear me?
10	DR. ZIEMER: Yeah. Ray, we did we lose you
11	for a while or were you recording?
12	THE COURT REPORTER: No, we're on.
13	DR. ZIEMER: Gen had asked whether you can
14	recognize us by our voices or whether or not
15	you wanted each Board member to identify
16	themself when we talk.
17	(No response)
18	DR. WADE: Ray, can you hear us? We're not
19	hearing you.
20	THE COURT REPORTER: Yes, I'm hello?
21	DR. WADE: Yes.
22	THE COURT REPORTER: I'm hearing y'all fine.
23	DR. WADE: Okay, there are there are long
24	periods when we're not hearing you respond to -
25	_

1	THE COURT REPORTER: I know it
2	DR. WADE: so that causes us concern.
3	THE COURT REPORTER: Do you want me to go to
4	another phone?
5	DR. WADE: Have you missed any of our
6	deliberations?
7	THE COURT REPORTER: Excuse me?
8	DR. WADE: You have not missed any of our
9	deliberations?
10	THE COURT REPORTER: Oh, no. No.
11	DR. ZIEMER: Ray, do you want the Board members
12	to identify themselves when they
13	THE COURT REPORTER: No.
14	DR. ZIEMER: speak or can you recognize
15	voices?
16	THE COURT REPORTER: It's not necessary. I'm
17	fine without that, but I'm wondering if I
18	should move to another phone so y'all can
19	communicate with me.
20	DR. ZIEMER: Oh, no, that's all right. This is
21	always I think that probably probably
22	good to identify, just to double make
23	double-sure.
24	THE COURT REPORTER: Usually I'm fine with it.
25	DR. WADE: Okay, Ray, and this is Lew Wade.

1	I've sent people to find you, so when they
2	come, that's why they're looking for you.
3	THE COURT REPORTER: Okay.
4	DR. ZIEMER: Okay, Board members, you now have
5	the proposed teams for round six. Is there any
6	objection or comments on those teams?
7	MR. PRESLEY: This is Bob Presley. I have no
8	problems.
9	DR. ZIEMER: Anyone have any concerns about
10	MR. GRIFFON: Yeah, Paul, this is Mark Griffon.
11	DR. ZIEMER: Yeah.
12	MR. GRIFFON: I don't have any concerns with
13	the teams and I let the process go, but I do
14	want to say for the record, I think my
15	conflicts are wrong again so I've got to talk
16	to
17	DR. ZIEMER: You need to work that out
18	MR. GRIFFON: them, yeah.
19	DR. ZIEMER: with the attorneys and then we
20	can hopefully
21	MR. GRIFFON: I only see one site on here that
22	I should have been conflicted on, one case, and
23	I don't understand. I think they're recusing
24	me Oak Ridges again and that's not the
25	case, so

1 DR. WADE: Okay, we'll work that out, Mark. 2 Thank you. 3 DR. ZIEMER: Thanks. Then without objection, 4 these'll be the assignments for then the next 5 set of cases. And perhaps -- perhaps Kathy and Hans can give us some idea of timetable on this 6 7 set. Or John. 8 MS. BEHLING: Okay, this is Kathy Behling. 9 am hoping to have this sixth set done by the 10 next meeting in December, so hopefully -- I'm 11 not sure if we're going to get out conference 12 calls in before the next meeting or somewhere 13 right after that meeting, but it's going to be 14 very close to the December meeting. 15 Yeah. But we -- we then, for the DR. ZIEMER: 16 December meeting -- as far as looking ahead --17 we will have round four matrix to deal with 18 'cause that's already underway. 19 MS. BEHLING: That's correct --20 DR. ZIEMER: And then we'll have the first 21 round -- the first sort of version of the 22 matrix and the findings for this set. 23 MS. BEHLING: Yeah. Actually the matrix for 24 the fourth set I have -- I have initiated and 25 developed that matrix. I believe that's in

NIOSH's hands at this point in time. We haven't gotten any response yet. I understand they're backlogged and I am -- when we get through with tomorrow's conference call I will develop the matrix for the fifth set and I will -- we will circulate that. And then hopefully very close, as I said, to the December meeting we will be near done with the sixth set and will probably just be having conference calls about that time. And then after the conference calls, again, we will publish our report and generate the matrix for the sixth set. So there's going to be three sets of matrices that are going to require issues resolution by the end of this year.

DR. ZIEMER: Right. And Mark, just in terms of the -- the subcommittee now, we'll be hopefully operating in the new subcommittee mode by the time of our December meeting. I think the new -- new document is still going through the system, but at least -- there will be at least two matrices to address at that point.

MR. GRIFFON: Yeah, that -- that's right.

DR. ZIEMER: Okay.

MR. GRIFFON: And we might even want to have --

1	I have to coordinate with Stu, as well, 'cause
2	to see where he is with the NIOSH responses
3	on the fourth, but I was actually hoping
4	possibly to have a subcommittee meeting prior
5	to the full Board meeting.
6	DR. ZIEMER: You mean
7	MR. GRIFFON: That may not happen, though,
8	depending on the the progress of
9	DR. ZIEMER: You mean separate or
10	MR. GRIFFON: Separate, separate from, yeah.
11	DR. ZIEMER: Yeah.
12	DR. WADE: Stu, are you on the line? Is there
13	any comment that NIOSH can make at this point?
14	MR. HINNEFELD: Yeah, I'm on the line and I
15	think we can probably make a working group
16	meeting or be prepared for a working group
17	meeting before the next
18	MR. GRIFFON: It would actually be a
19	subcommittee now
20	MR. HINNEFELD: Yeah, yeah, but before the ne
21	MR. GRIFFON: Before it was a work a work
22	MR. HINNEFELD: meeting
23	MR. GRIFFON: session.
24	MR. HINNEFELD: Yeah. But we'll have to check
25	our calendars, Mark. There's

1 MR. GRIFFON: Okay, we can --2 MR. HINNEFELD: Looks like we can be ready 3 about Thanksgiving time, I think, but maybe we 4 can beat it by a week. MR. GRIFFON: Okay, so it may not be 5 6 advantageous to even -- we can -- I can talk to 7 you more, Stu, on that and we can --8 MR. HINNEFELD: Right. 9 DR. ZIEMER: And then, just thinking ahead, we 10 need to be thinking about the next set of cases 11 after that, selection process for that, too. 12 DR. WADE: Right. 13 DR. ZIEMER: Okay, any -- that is actually what 14 the business is on the -- on the dose 15 reconstructions. Any -- any other comments or questions on that item? 16 17 (No responses) CONFLICT OF INTEREST UPDATE CONCERNING THE SC&A CONTRACT 18 19 If not, we can move on to the conflict of 20 interest item on the agenda. This is -- this 21 is an item concerning the SC&A contract and the 22 conflict of interest. And there are a couple 23 of parts to this. One -- one of them had to do 24 with the fire-- so-called firewalls, and I

think you've gotten the correspondence from

25

David Staudt. I don't know if David's on the

MR. STAUDT: Yes, Dr. Ziemer, I am.

DR. ZIEMER: Okay, good. So -- and Lew, did you have -- want to kick this off and then maybe David can follow up there?

DR. WADE: Only to turn it over to David and to -- to make his report, and then look forward to a discussion about sort of paths forward to -to satisfy the Board's issues and concerns.

MR. STAUDT: Dr. Ziemer, the first issue related -- was related to the firewall mitigation strategy which you -- you wanted me to come back and take a look and see if I could get that incorporated into the contract. And I took a look at the contract and the conflict of interest plan is incorporated by reference into the contract, so I won't be modifying the base contract. But the conflict of interest plan is a living document and SC&A is required every December to review the plan to make sure that it's up to date and if there are any changes to be made. Now they've only had to do that once, and now it's coming up this December again and I've asked them to include the firewall plan in their -- in any of their comments to me. So

I'm fully anticipating that the plan will be

updated and that we will have a revised plan in

December or January and that will be sent to

the Board and also be put on the web sites. So

I think that issue's pretty much -- I think

that's been resolved.

The other issue that comes up has to do with what I just call conflict -- special conflict of interest, circumstances or situations that - and -- and I know that during the performance of this contract several of these are going to come up and some are very minor. But some are -- are more serious and -- and how are we going to address those and I think that's what Lew was alluding to that. I think we need to have some discussion on how the Board would like to see this done 'cause there was a concern that the Board mee-- only meets, you know, every so often and if these -- if these issues come up, how was the Board going to be informed.

So from my perspective these conflict of interests can -- can be derived or -- or the concerns be raised from -- from anyone. And the main thing is that either Lew -- Dr. Wade

25

1

or myself be informed. And then it comes down to how are we going to deal with them. And I just put an example out there. One of the more difficult ones dealing with Dr. (unintelligible) and Anspaugh and their work at Nevada Test Site and the Pacific Proving Ground. And in that situation John Mauro came to us and said that he would like to use these experts and the reasons why. And -- and I of course had certain -- I knew that this was going to cause some difficulties, but we looked at the situation and Dr. Wade and I decided that -- that we were going to bound the work that they were going to do and -- and everything that they were going to do was going to be transparent to the working group. under those very limited circumstances, when their work was done, these gentlemen are going to have to stop performance on the contract. So I think that some members are -- are -- want to maybe have a -- they may have an input or have some -- some notification provided to them that -- in these circumstances. And I kind of want to get a feel from the Board exactly what they're looking for. You know, my goal always

is to make sure that this mov-- this work keeps moving forward and that when these situations come up there are no delays. So I don't know if Dr. Wade or you want to kind of make some comments on that, but I just want to get a feel from the Board on how they would like to see this proceed.

DR. MELIUS: Yeah, let me --

DR. WADE: This is Lew. I mean I can provide a little bit of background and just to sort of bin the problems and then to -- to have the Board provide guidance.

When it goes to an issue of approving a variation in the plan -- the conflict of interest plan, for example -- there are responsibilities that fall to the government. There are also responsibilities that I think the Board wants to hold for themself in terms of letting their opinions be known. In order for the -- for the Board to do that, there needs to be a complete and accurate disclosure of information on the part of SC&A. We have to talk about how that takes place. Then we have this last issue which is the decision-making authorities of the Board. The Board can only

take a formal action when they're together with a quorum. But we do have working groups and we've given certain prerogatives to chairs of working groups. So the government can exercise its own prerogatives in terms of its opinion, but I'm very interested in knowing what the Board would like the government to -- to await to hear from the Board on with regard to these issues.

DR. ZIEMER: Yeah, and it may vary in every case, but we -- we have a specific case here that maybe can help give us some guidance. For example, here is the case where I think, from the government's point of view and putting some boundaries on it, you have -- and keeping the transparency, you -- you have indicated that you believe that it meets the government criteria for handling COI. At the same time, there are concerns that the Board, or at least maybe individuals on the Board have about individuals involved and their roles, and some means of providing that input at the front end, before things are sort of an accomplished fact and -- and whether or not working groups -- I -- I don't think we've explicitly authorized

working groups to act on behalf of the Board except in limited ways in terms of discussions on, you know, what kinds of information they would like when they're work-- working, say with NIOSH, and trying to develop matrices and so on. But certainly final actions are always things the Board has to do. So perhaps some general comments from Board members and we can determine whether we need a more specific policy or not.

DR. MELIUS: Yes. This is Jim Melius and I was the one that raised this issue. And what I was disturbed about was that there was no consultation from NIOSH back -- and the contracting office back to -- to the Advisory Board about how these two particular individuals would be used. So -- and we weren't, you know, sort of fully informed about their potential conflicts of interest and then we're -- suddenly been confront with a -- you know, that they were on board, I -- you know, as -- as participants. We weren't informed about what their limitations were and I personally think that those limitations were not appropriate and certainly would have liked

to had some input into the process of how that was -- how that was determined and was not allowed that. And -- and frankly it caused a fair amount of conflict between John Mauro and I about -- 'cause, you know, he's telling me he had the go-ahead to use them in a way that I -- I thought wasn't appropriate and this -- they're -- at least one of them is involved in the 250-day issue, which is relevant to the workgroup that I chair.

What I would like to have going forward -- and I believe we've done this before -- appropriate -- is that, you know, you doctors -- you know, one is that the Board members be informed when this kind of a situation is tak-- taking place with, you know, our contractor, SC&A and -- and they be fully informed so that we understand what -- what's going on. Secondly, that -- you know, I -- I don't have any problem -- and that then we be given an opportunity to maybe express our views to Dr. Ziemer as the Chair of our Board. Alternative may be that, you know -- in this particular case, since it -- it takes in -- involves the Nevada Test Site, Bob Presley and I were chairs of the -- the working

groups that were most -- you know, most involved in this issue and, you know, Paul -you know, would -- would consult with us and -and we'd try to resolve -- I don't think that would necessarily hold it up and I think this could have been resolved, you know, fairly easily and allowed the work to go forward. But I didn't think it was appropriate that this went ahea-- you know, essentially that NIOSH was in a position of making a -- in the contracting of it, a decision about our contractor without consulting us. And in essence, it's our credibility that's on the line, not NIOSH, and -- and you know, so it's a tricky situation to -- to deal with.

DR. WADE: This is Lew. One of the issues that we need to deal with -- and again, I'm completely sensitive to everything Dr. Melius says, is -- is where the responsibility would fall for notifying Board members. When NIOSH was notified of this by John Mauro, we were notified in an e-mail that also indicated that he had copied the chairs of the working groups, Dr. Presley and -- Mr. Presley and Dr. Melius. And so we operated on the assumption that that

notification was made. We need to crisp this up because obviously it didn't work --

DR. MELIUS: Yeah, well --

DR. WADE: -- and --

DR. MELIUS: -- two -- two problems with that. We did receive an -- an e-mail, copy of the email, but then there was, you know, essentially no consultation back from you or Da-- or Dave Staudt about -- about -- about the issue, and next thing you know, it was -- was done. Secondly, I did not think that -- that John's information was complete and, at least based on some of the information I -- I obtained later from -- actually from SC&A web site and so forth. Now, I -- I -- again, I think John was making a good-faith effort to -- to provide information to us, and I think if we had been consulted, if there had been some way -- you know, some system in place to get back to us, I would have asked for additional information based on John's e-mail and -- and then we could have, you know, worked to -- to get it resolved and I think it could have been done in -- in a timely manner. But -- but I was basically expecting, you know, to hear back from you and

24

25

1 -- and you know, I believe that was the time 2 you were out of town, Lew, so I mean there was 3 some, you know, reasons --4 DR. WADE: Right, this is always about making 5 good process in the future. 6 DR. MELIUS: Yeah. 7 DR. WADE: -- we study the past to understand 8 how to do the future better, so -- so again, in 9 terms of this process, would the Board expect 10 to be notified of these issues by SC&A or by 11 the contracting officer once the contracting 12 officer is notified by SC&A? 13 MR. PRESLEY: This is Bob Presley. I think it 14 ought to be by the contracting officer. 15 MR. STAUDT: I -- I would be -- this is Dave Staudt. I would be more than happy to do that. 16 17 DR. WADE: Okay. So once -- then once that 18 notification is made, is the action then on the 19 part of Board members to contact Dr. Ziemer 20 with concerns, or would you like there to be --21 I can't schedule a call of Board members, so there needs to be a step forward. Once a Board 22 23 member receives notification, what would Board 24 members like to see as their range and actions? 25 DR. MELIUS: This is Jim Melius again. I would

1 say that we -- we contact Dr. Ziemer. 2 DR. WADE: Okay. 3 DR. MELIUS: You know, maybe copy you, Lew and 4 Dave, on, you know, any concerns that we raise, 5 but that, you know, it's our responsibility to 6 contact Paul and -- if there -- if there is a 7 concern about something. That's --8 DR. WADE: And I think that's very workable, so 9 10 DR. MELIUS: I -- I --11 DR. WADE: -- just to repeat, if a situation 12 comes up relative to an exception to the conflict of interest policy on the part of 13 14 SC&A, SC&A's contractually responsible to 15 notify the contracting officer. contracting officer then takes the 16 17 responsibility to notify individual Board 18 members. At that point individual Board 19 members will contact Dr. Ziemer if they wish to 20 pursue this further in terms of asking for 21 information, raising a question, any 22 interaction they would like they would do so by 23 contacting Dr. Ziemer, who would then con--24 contact the contracting officer.

This is Bob Presley. I agree

MR. PRESLEY:

25

with that.

DR. ZIEMER: Well, let me ask a question here first. This is Ziemer again. Now are we assuming that David will know which workgroups are the ones that need to be contacted?

DR. MELIUS: That's why I was -- this is Jim, sorry to interrupt, but I would say it goes out to all the Board. That way we're not having to worry about what -- what workgroup and so forth.

MR. CLAWSON: That -- this is Brad Clawson. I agree with that because there may be other people on other workgroups that may know things that the actual workgroup don't about this individual.

DR. ZIEMER: Right. So the full Board would get contacted under this proposal, and then I think work-- I think particularly in a case like the one we just talked about, I think between the workgroup chairs then and the Board Chair we could make a determination if we felt the issue rose to the level where we needed the full Board sort of conference call or whether we could resolve it informally without -- without going through a -- a Board action

1 process. 2 DR. WADE: Right, I would expect that after the 3 notification of all the Board members, Dr. 4 Ziemer, you can consult one on one with working 5 group members and at that point you would have the option of calling the contracting officer 6 7 and say the Board would like you to delay 8 decision on this --9 DR. ZIEMER: Uh-huh. 10 DR. WADE: -- till the Board formally meets. 11 DR. ZIEMER: Right. 12 DR. WADE: David doesn't have to follow your 13 recommendations, but you can make that 14 recommendation --15 DR. ZIEMER: Understood. 16 DR. WADE: -- to him and --17 DR. ZIEMER: Understood. 18 DR. WADE: -- in all likelihood he would 19 attempt to follow your recommendation. If he 20 doesn't hear from you, then he could proceed 21 with making his judgment. That seems 22 reasonable to me, it seems workable. 23 DR. ZIEMER: Right. And the -- the other part 24 of this is to -- we need to make sure that the 25 -- for -- for example, I don't know if all the

1 Board got this -- yeah, David, you -- you 2 distributed your -- your memo of the 18th to 3 all the Board members, I believe. 4 MR. STAUDT: Yes. And -- and that had -- that had 5 DR. ZIEMER: John's e-mail of August 30th attached to it --6 7 or as part of it. 8 MR. STAUDT: Correct. 9 DR. ZIEMER: But --10 DR. WADE: But John's e-mail -- for the record, 11 John Mauro's e-mail was only sent to the two 12 working group chairs that he thought had --13 DR. ZIEMER: Right, and what I'm saying is that 14 -- that -- that's too much delay. So for 15 example, an e-mail like John's e-mail of August 16 30th, if received by the contracting officer, 17 should immediately go out to the Board --DR. WADE: Correct. 18 19 DR. ZIEMER: -- at that point, before any 20 action is taken on the part of the contracting 21 officer. 22 DR. WADE: Correct. 23 DR. ZIEMER: Yeah. 24 DR. WADE: And then the contracting officer 25 would wait an appropriate time to make a

1 decision, likely make a call to you, Dr. 2 Ziemer. 3 DR. ZIEMER: Yeah. In other words, he would 4 say here's a proposal or request from the 5 contractor on this particular issue. Does the 6 Board wish to take a position or delay action 7 or whatever. 8 DR. WADE: Correct. 9 DR. ZIEMER: Are other Board members 10 comfortable with this approach? 11 MR. PRESLEY: This is Bob Presley. I am. 12 MS. MUNN: This is Wanda. It seems workable. 13 DR. ZIEMER: Any -- any that want to voice a 14 contrary opinion or propose an alternative? 15 DR. ROESSLER: Sounds good to me. 16 DR. MAURO: Dr. Ziemer, this is John Mauro. 17 DR. ZIEMER: Yeah. 18 DR. MAURO: By way of confirmation then, when I 19 notify David of such a situation, we take -- we 20 sit tight until we hear back from the 21 contracting officer with a green light or not. 22 DR. ZIEMER: Right, and so --23 DR. MAURO: We don't do any work along those 24 lines until we hear back. 25 DR. ZIEMER: Well, in a case like this, yeah,

you -- in other words, you -- you've proposed a way to proceed and you're waiting for a green light to do so. David in turn will be evaluating it from the government's point of view and also notifying the Board and asking the Board if we have particular concerns and want any particular delay to address them, I think is -- is the essence of it. Is that your understanding, too, David?

(No response)

Is David still on the line?

MR. STAUDT: Yes, it is.

DR. MELIUS: Yeah, and -- Jim Melius. Just to add, in this particular case I think, you know, both John and David were -- were trying to get this in place because of the issue with SC&A and the DTRA contract. You know, we'd already delayed some time in terms of their involvement at Nevada Test Site, so you know, they were trying to expedite this and -- in these circumstances, so I -- I think it -- and we just didn't have a -- a -- you know, a procedure in place to -- to deal with it.

DR. ZIEMER: Right.

DR. MELIUS: It really hadn't come up before --

1	<b>DR. ZIEMER:</b> Right.
2	DR. MELIUS: so but my my concern is
3	basically going forward. What's happened has
4	happened.
5	DR. ZIEMER: Yeah, yeah.
6	DR. WADE: Yeah, my considered opinion this
7	is Lew is that everyone was acting in the
8	best interest of the process. But again, it
9	was we were in a place we had not been
10	before and it's always good to have plans.
11	DR. ZIEMER: Okay. Well, we'll proceed in that
12	fashion then and the this is kind of an
13	informal process. We'll see how it works.
14	DR. WADE: All right. With everyone's
15	permission, I'll write this up and send it just
16	as a note to the Board so Board members
17	individually can correct my recollection of
18	this. And if not, we'll have something to
19	refer to.
20	DR. ZIEMER: Thank you. Any other comments on
21	this issue?
22	(No responses)
22	WORKING GROUP (WG) REPORTS AND SCHEDULING FOR
23	FUTURE WORK GROUP MEETINGS
24	Okay, very good. Then let's move ahead to
25	working group reports. Now we have a sizeable

list of working groups now. In fact, if you —
if you go back to a — some correspondence that
Lew distributed after our last meeting, and
it's an e-mail dated September 26th, is a kind
of a roster of all the workgroups, as well as
the subcommittee. And I think it would be
appropriate if we went through each of those
and at least got a status report on where they
are in terms of either scheduling meetings,
already scheduled between now and the next
Board meeting or planned meetings or any other
things pertaining to where they are on their
particular issues.

Let's see --

DR. WADE: Dr. Ziemer, I could just run down the list if you would like.

DR. ZIEMER: Yeah, why don't we -- we can just do it in order, beginning with the Subcommittee on Dose Reconstruction.

DR. WADE: And again as background -- you know, putting the agenda together for this call, I -- I didn't indicate that we would have in-depth technical discussions of -- of any of these issues. I think sort of a summary status report by the working group chair, and I'm

25

particularly interested in scheduling working group meetings. There's been a flurry of emails that could cause one to think some meetings are scheduled or not, and I think it would be good, at one time at one place, to get all of that on the record so we could be sure that the working group and subcommittee's needs with regard to future meetings are met. I'd start with the Subcommittee on Dose Reconstruction, ably chaired by Mark Griffon. MR. GRIFFON: Yeah, we -- as -- as you just heard, I think I might need to talk to Stu a little further and SC&A and -- and the subcommittee members, but I was hoping to have a -- a subcommittee meeting prior to the next Board meeting, only because we can -- it -- we can have a more focused working session if they're -- if they're separated from the Board meetings. I think we -- it allows us to focus totally on the matrix and go through the matrix one item at a time. If it's going to be too close to the Board meeting by the time everyone's ready, I think we'll probably just have a meeting the day before the regular Board meeting and move on matrix -- the fourth matrix

1 and, to the extent we can, the fifth matrix, 2 but at least the fourth matrix. I think we're 3 ready to -- to go into -- to finding 4 resolution, comment resolution process. 5 DR. ZIEMER: Right. 6 MS. MUNN: This is Wanda. When you were 7 discussing that earlier I was trying to express 8 my -- my concurrence that we need to get that 9 one really moving and moving very quickly and -10 - and I was -- there was something wrong with 11 my microphone apparently. I had to get rid of 12 it. 13 MR. GRIFFON: Oh. 14 MS. MUNN: But -- can't -- can't stand to have 15 you not hear me. 16 MR. GRIFFON: Yeah, I think Stu -- Stu has been 17 putting together responses for NIOSH, so we 18 want to at least have -- give NIOSH adequate 19 time to fill that part of the matrix in before 20 we schedule a meeting. 21 MS. MUNN: I would certainly hope so --22 MR. GRIFFON: Yeah. 23 MS. MUNN: -- but when you suggested let's go 24 with the other meeting the day before our other 25 meeting, we're currently scheduled -- if my

1 calendar tells me correctly -- to start on a 2 Monday. Am -- am -- is my calendar correct or 3 am I incorrect? 4 DR. WADE: Calendar's correct. 5 MS. MUNN: I -- I was scheduling 11th of December as our first meeting date. And if 6 7 that's the case, then -- then it would 8 certainly be helpful, from my point of view, if 9 we did that the week after Thanksgiving rather 10 than -- than --11 DR. WADE: Wanda, the last thing we heard was 12 "if we did that" and now we're not hearing you. 13 MS. MUNN: Oh, you're not? There was a strange 14 sound, but again, it wasn't me. 15 I can hear you. MR. GRIFFON: 16 MS. MUNN: Good. My suggestion was that the 17 week after Thanksgiving would -- if -- if it's 18 possible at all for Stu to get the materials 19 together that we need to do, would probably be 20 much better than waiting until the week before 21 the meeting since our meeting starts on Monday. MR. GRIFFON: Yeah, and I was assuming that the 22 23 Monday was left for subcommittee meeting time 24 anyway, but maybe it wasn't. 25 DR. WADE: No, it might be. We'll have that

discussion later --1 2 MR. GRIFFON: Yeah. 3 DR. WADE: -- but --4 MR. GRIFFON: I -- I agree, if we can get it 5 in, Wanda. The only thing I wouldn't want to do is like the week before wouldn't make a lot 6 7 of sense. 8 MS. MUNN: No, it would --9 MR. GRIFFON: If it can be a couple of weeks 10 before, then let's -- let's try to do that, 11 yeah. 12 MS. MUNN: If we could just do the last -- the last week in -- in November, that would --13 14 MR. GRIFFON: Right. MS. MUNN: -- that would be ideal I think if 15 16 Stu could do it. MR. HINNEFELD: This is Stu Hinnefeld. How do 17 18 you feel about the week before Thanksgiving 19 rather than the week after? 20 MS. MUNN: Well, the week before is fine for me 21 if it's fine for you. I just --MR. HINNEFELD: Well, the week --22 23 MS. MUNN: -- thought that might be --24 MR. HINNEFELD: -- after is not fine --25 MS. MUNN: -- pushing you too much.

1 MR. HINNEFELD: The week after is not fine for 2 me for -- I'd say personal reasons. 3 MS. MUNN: Okay. But we're -- we're going to 4 have working group meetings in Cincinnati the 5 preceding week, at least one, on the 9th, and -6 - and possibly more, either before or after 7 that. But if -- from my perspective, if you 8 can get what you need together by the week of 9 the 13th, that would be --10 MR. GRIFFON: Okay. 11 MS. MUNN: -- the best of all possible worlds, 12 if you --13 MR. GRIFFON: We'll have to work on that. 14 think, Wanda, a lot of us have the similar 15 idea, which is -- I was thinking if I can tie 16 my Rocky Flats workgroup along with the 17 subcommittee, you know, and travel once instead 18 of twice --19 MS. MUNN: Right. 20 MR. GRIFFON: -- that would be ideal. 21 MS. MUNN: Right. 22 MR. GRIFFON: So we need to coordinate these, 23 as well. But yeah, if we -- let me -- let --24 let's do this. Stu, do you -- I mean do you 25 want to lock into a day or you want to check

1 with your folks first? 2 MR. HINNEFELD: Well, we -- we require some 3 more interaction with ORAU before we --4 MR. GRIFFON: Okay. 5 MR. HINNEFELD: -- we know we're going to be ready so I'd -- I'd rather not --6 7 MR. GRIFFON: All right. 8 MR. HINNEFELD: Or you can -- you can pick a 9 day today and I can -- you know, in association 10 with other meetings when you're going to be in 11 town, and then we'll just do whatever we can to 12 get ready. DR. ZIEMER: I think, Lew, for your purposes 13 14 you can indicate they're shooting for the week 15 of the 13th. Right? 16 MR. GRIFFON: Yeah. 17 MS. MUNN: Yeah, can we take --18 DR. ZIEMER: Maybe as the other workgroups 19 report and we see --20 MR. GRIFFON: We can see where --21 DR. ZIEMER: -- schedule, we can try to 22 coordinate those. 23 DR. WADE: I think at the close of this I'd 24 like to have a day -- a specific day for the 25 subcommittee.

1 DR. ZIEMER: Yeah. 2 DR. WADE: Let's wait until that decision is 3 informed by others. 4 MS. MUNN: That's a good idea. I would -- I would propose that -- the 16th, if that looks 5 as though it's going to be --6 7 DR. WADE: Check. 8 MS. MUNN: -- (unintelligible) for others. 9 DR. WADE: We won't end this without the 10 possibility of trying to lock in a day, but 11 let's hear some more. 12 Now again, the -- for -- for everyone's 13 recollection and the record, the subcommittee 14 is chaired by Mark, with Mike Gibson, Dr. 15 Poston, Wanda; alternates are Clawson and 16 Presley. 17 Then we have -- the next on the list that I 18 sent out was the workgroup on the Nevada Test 19 Site site profile, chaired by Presley with 20 Munn, Clawson and Roessler as members. 21 Robert, you know, in a nutshell, where are you, 22 what are you scheduling? 23 MR. PRESLEY: Okay, this is Bob Presley. 24 have not -- we do not have anything scheduled. 25 I'm waiting on -- Is Mark Rolluf (sic) there

1 today? Is Mark listening in? 2 DR. NETON: Mark is here but not -- I don't 3 believe he's on the phone right now. 4 MR. PRESLEY: Okay. What we're waiting on is 5 CDC, NIOSH, to go through a proposal and then 6 come back to us with a date that we can get 7 together. I have talked -- myself talked to 8 Mark last week and we've not talked since then 9 about a date, but I would -- I would hope that 10 we could probably set our meeting sometime 11 around this -- either before or after this 12 November the 13th date so that -- because the -13 - some of the people that are on the NTS working group are also on the Rocky Flats. 14 15 DR. NETON: Bob, this is Jim Neton. 16 that there was some concern about our response 17 to the Anspaugh write-up --MR. PRESLEY: 18 That's correct. 19 DR. NETON: -- and yesterday I believe we asked 20 ORAU, Gene Rollins specifically, to start 21 working on that. And I think it was -- their -22 - their thought was that it might take about 23 three weeks to -- three to four to accomplish 24 that analysis. So you know, if that's 25 something you want to be discussed at the next

1 meeting, it would have to be probably after the 2 13th. That -- that's up for you guys to 3 decide. 4 MR. PRESLEY: Okay. I will get back with Mark 5 on that --DR. NETON: Okay. 6 7 MR. PRESLEY: -- and see, because there's --8 what we had planned on doing is have Anspaugh 9 there with -- I don't have my notes --10 DR. NETON: Gene Rollins. 11 MR. PRESLEY: Lew (sic) Rollins, right, and 12 SC&A and the working group to go over this. 13 DR. NETON: Right. And again, the resuspension 14 calculations that -- that Anspaugh believes are 15 in error, to put some bracketing values around 16 those is going to take three to four weeks for 17 Rollins to accomplish that. Now it may be that 18 he can get to a point where he can get a 19 general sense of how -- the big -- the big 20 issue is how much difference does it make. I 21 think everybody agrees there's an error there, 22 but is it -- is it a significant error; and if 23 it is, how big. So I think you're right, we 24 need to get back with Mark and -- and flesh 25 that out a little better.

1 MR. PRESLEY: I will -- I will get back with 2 Mark tomorrow sometime. 3 DR. NETON: Okay, I'll let him know that. 4 MR. PRESLEY: Okay. I appreciate that. 5 DR. WADE: Thank you all. Next on the list is 6 the Savannah River Site site profile workgroup 7 8 DR. ZIEMER: Okay, did we announce who was on 9 the Nevada Test Site --10 DR. WADE: -- chaired by Mark (sic) Gibson. 11 DR. ZIEMER: Excuse me, Lew. Did you indicate 12 who was on the Nevada Test Site profile team? 13 DR. WADE: I will again. I think Presley, 14 Munn, Clawson and Roessler. 15 DR. ZIEMER: Uh-huh. 16 DR. WADE: On Savannah River Site it's Gibson, 17 Clawson, Griffon and Lockey. 18 MR. GIBSON: Okay. This is Mike. We have not 19 had any meetings or phone calls, the working 20 group, since the last one. I've been in 21 contact with Joe Fitzgerald with SC&A and Sam 22 Glover of NIOSH, and they're still exchanging 23 information, try to come to closure on some of 24 the open issues. It looks like they're --25 they're tightening them up. There's a few

things about the fault tree databank compilation about the other nuclides for the tank farm, and there's some so-called three by five-inch data cards that have some dose re-results on them that they need a little bit more exchange between the two parties where it'd probably be beneficial to have another meeting to try to close out multi open issues. But hopefully if -- if things go right, maybe we could plan a meeting that same week of November 13th for this working group also.

MR. CLAWSON: Mike, this is Brad Clawson. What was -- what was the name of that incident database that we were trying to get from the previous contractor for Savannah River? Have we had any response to that? I believe DuPont owned it and we were trying to get access to

MR. GIBSON: That I've not heard yet. I don't know if they've been made -- that's been made available to them or not.

DR. NETON: Yeah, we -- we can't answer that from this end, either. Sam Glover is our lead on that and he's not on the call.

MR. CLAWSON: Okay, that -- that's one thing
that I'd personally like to be made aware of
because I feel this is pretty important in this
one that we've got going on.

MR. GIBSON: Right, and you're absolutely right. And what's been brought up, this was paid for by government money supposedly so, you know, it should be available to us and the government and our contractor.

MR. CLAWSON: That's correct.

DR. WADE: Okay, let's move on to possibly the -- one of the most sensitive of issues and that's the workgroup on the Rocky Flats site profile and SEC petition chaired by Mark, with members Gibson, Presley and Munn.

MR. GRIFFON: Yeah, since the last meeting we've had a fair amount of activity by both NIOSH and SC&A responding to various action items. And I think at this point one of the critical items that -- that remains is the data reliability question. I think a lot of other ones are -- are close to closure, so -- but -- but I think again we're -- we're -- I'm -- I was thinking of early November or sounds like this week of November 13th could be a busy one.

1	MS. MUNN: Aren't we already scheduled for the
2	9th?
3	MR. GRIFFON: Did we schedule for the 9th?
4	MS. MUNN: We originally did.
5	MR. GRIFFON: I don't reca
6	MS. MUNN: At least on my calendar.
7	MR. GRIFFON: Oh, I didn't recall that.
8	MS. MUNN: Yeah, we had said the 9th. We
9	picked that
10	MR. GRIFFON: Did we say that in Vegas?
11	MS. MUNN: at our last meeting, yeah.
12	MR. GRIFFON: Okay, I was a little distracted
13	in Vegas when I left, so
14	MS. MUNN: No wonder why.
15	MR. GRIFFON: Yeah.
16	DR. ZIEMER: Mike, did you have that on your
17	calendar?
18	MR. GIBSON: No, I did not.
19	MR. PRESLEY: This is Bob Presley. Now I
20	didn't have that on my calendar, either.
21	MS. MUNN: Oh, boy, I
22	MS. HOWELL: This is Emily Howell. I had on my
23	calendar a meeting on the 9th for Dr. Lockey's
24	
25	DR. LOCKEY: Right.

1 MS. HOWELL: -- workgroup for SEC petitions not 2 qualifying. And Wanda, I think you're in that 3 group, as well. 4 MS. MUNN: Yes, I am. 5 MR. GRIFFON: Ah, that's a different meeting. 6 DR. LOCKEY: That's the meeting for the 9th. 7 This is Lockey. 8 MS. MUNN: That may be -- that may be what I 9 had written down and -- and was thinking --10 thinking Rocky Flats and --11 DR. WADE: And that's why we're here having 12 this discussion 'cause there's been a lot of this sort of miscommunication, but that's fine. 13 14 So Mark --15 MR. GRIFFON: Yeah, I -- I have -- I mean I 16 would like to, again, link it around these 17 other times, maybe even like the 8th -- 'cause 18 it looks like we're going to have busy two 19 weeks and a lot of people are on several 20 workgroups, so --21 MS. MUNN: Yeah, we are. 22 MR. GRIFFON: -- you know, it may be --23 MR. PRESLEY: Mark, this is Bob Presley. The 24 8th is not good -- the 8th or the 9th is not 25 good for me.

1 MR. GRIFFON: Okay. 2 MS. MUNN: Is the 10th? 3 MR. PRESLEY: Friday the 10th? No, because I 4 can't get up there -- well, unless I can get an 5 early flight out of here. 6 MS. MUNN: You can get an early flight, Bob. 7 MR. HINNEFELD: Friday the 10th is a holiday 8 for federal employees. It's -- Veterans Day is 9 observed. 10 MR. GRIFFON: Oh, okay. 11 MR. PRESLEY: That's right, yeah, and I need to 12 be -- I need to be somewhere around here for 13 that, too. 14 MS. MUNN: So that means if we're going to do 15 that week and hold to the 9th that we already 16 have scheduled, we'd have to be looking at 17 something like election day on the 7th or 18 something of that sort. 19 MR. GIBSON: And we can't miss that. 20 MS. MUNN: No -- well --21 MR. GRIFFON: Yeah. 22 MS. MUNN: -- you can -- you can vote before 23 you leave. I do that all the time. 24 MR. GRIFFON: I mean my -- my sense from -- I 25 did talk to Joe Fitzgerald a little bit and

20

21

22

23

24

25

they are drafting sort of a review of the evaluation report as all this stuff -- all these action items come in and NIOSH's responses come in. SC&A has been drafting sort of their review of the evaluation report and also they've drafted some analysis of the completeness of the individual dose files or the dose record and I think that's going to be a critical one in sort of winding up this question of data reliability. So he -- Joe indicated that probably they would need at least till the end of October, early November. So I think -- we might be able to do it earlier. I was just trying to figure out -you know, I don't -- I don't want people to have to travel to Cincinnati three times in three weeks, you know.

MS. MUNN: No, I think --

MR. GRIFFON: So --

MS. ESCOBAR: Mark -- Mark, this is -- this is Felicia with Senator Salazar and we just -- just wanted to, you know, say that we're still following this issue and, you know, I think that the data reliability issue is something that, you know, from our constituents'

21

22

23

24

25

perspective it's been a -- you know, it's -continues to be a really big problem and, you know, we would hope that you guys would -understanding that it's difficult with travel for everybody and that this is a very timeintensive process, that you would -- you'd take the -- the appropriate, you know, time to really, you know, give -- give the parties the ability to really review and get into the -you know, the nuts and bolts of the data reliability issue, and also give, you know, you all as Advisory Board members the opportunity to really review what comes back from -- you know, from NIOSH and others, so that's just one thing I wanted to -- to make clear, that we're really hoping that you guys are able to really get -- get the information you need and have So just factor the time to -- to review it. that into your, you know, your --DR. WADE: Thank you. Thank you very much for

MS. ESCOBAR: Yeah.

that.

DR. WADE: So I guess the instruction that I would take is that we want to meet as soon as we can, that meaning when we are fully ready,

1 so -- because again, if we meet, then we might 2 have to meet again. Is it possible that early 3 in that week, even November 6th, might be an 4 opportunity? 5 MR. PRESLEY: This is Bob Presley. I could 6 make that day. 7 DR. ULSH: This is Brant Ulsh. I have some 8 questions -- this is the first I've really 9 heard about SC&A's analysis of the completeness 10 of individual rad files. If that is going to 11 come to us at the end of October, we'll need 12 some time to review that, depending on how big 13 it is. 14 DR. ZIEMER: Yeah. MR. GRIFFON: No, I think Joe -- Joe 15 16 Fitzgerald, are you on the line? 17 MR. FITZGERALD: Yes, I am. 18 MR. GRIFFON: I think that's ready to go soon. 19 Right, Joe? 20 MR. FITZGERALD: Yeah, I mean --21 MR. GRIFFON: At least as a preliminary report, 22 it is. 23 MR. FITZGERALD: Yeah, we think we can have 24 this thing teed up for the -- for NIOSH and the 25 Board, if not today, by early tomorrow. So

1 we're -- it's been in development now for a 2 week or so -- a couple of weeks. 3 MS. MUNN: Great. That's good to hear, Joe. Thank you. 4 5 And I hope that someone other than I is willing 6 to reassure the Congressional members who are -7 - are focused on the data reliability issue 8 that we are spending an -- a significant amount 9 of time and effort looking at this thing. I 10 hope we can reassure them that they need not be 11 concerned that it's going to be glossed over or 12 shortchanged in any way. We --MS. ESCOBAR: Well, I -- and I appreciate that. 13 14 This is Felicia again, you know, but we just 15 can't stress that enough and I -- and I know 16 that if it's as taxing on your time, so you 17 know, thank you for -- for really digging into 18 the issues. We really appreciate it. 19 DR. WADE: Right, and -- and I think -- this is 20 Lew Wade -- that the working group and the 21 Board's record will speak for itself on this, 22 so -- what about the 6th? I hate to --23 MR. GRIFFON: Yeah, we could tentatively do the 24 6th, but I think Brant, if you get this report 25 tomorrow, I think it's like -- like Joe -- Joe

1 mentioned it to me on the phone as being sort 2 of a preliminary review of -- of about 12 3 cases, Joe, is that what --4 MR. FITZGERALD: Yeah, we've done 12 cases and 5 this comes from, you know, the review that -- I think stems from the review that you've done on 6 7 HIS-20 versus CEDR and --8 MR. GRIFFON: Right. 9 MR. FITZGERALD: -- trying to go back to some 10 of the original claimant data, just to sort of 11 bring it around full circle as far as data 12 reliability. So I think you will have what you 13 would need to look at and consider, and I think 14 it -- certainly in -- in time, with a few weeks 15 perhaps, that we could have a discussion in 16 November. 17 MR. GRIFFON: Yeah, I did mention this is an ongoing activity. In the Vegas meeting my 18 19 notes say that SC&A was reviewing these at that 20 point, and I quess their -- their draft 21 report's final now. Or -- or it's a -- they --22 they've completed a draft, anyway. 23 DR. WADE: Okay, so the 6th is a Monday before 24 election day. 25 MS. MUNN: Yeah, let's go for it.

1	DR. WADE: I'm sorry, Wanda?
2	MS. MUNN: I suggest we go for it.
3	MR. GRIFFON: I think we should shoot for it,
4	yeah.
5	MS. MUNN: I hate to put this off if there is -
6	- if there is any since Joe's going to have
7	the material ready for us to really look at and
8	if Brant and if (unintelligible) available on
9	the 6th, then that's we we've really
10	spent a lot of time and
11	MR. GRIFFON: I think that's a good week, too,
12	because then it gives us several weeks before
13	the Board meeting
14	MS. MUNN: Right.
15	DR. WADE: Right.
16	MR. GRIFFON: where where some additional
17	work, if it needs to be done, can be done.
18	MS. MUNN: Any loose ends
19	MR. GRIFFON: Yeah.
20	MS. MUNN: can be addressed.
21	DR. WADE: Okay, very good. And I'm going to
22	be so bold as to suggest maybe 10:00 a.m. to
23	give some people a chance to fly in that
24	morning. Does that work for you, Mark?
25	MR. GRIFFON: That's great.

1 MR. PRESLEY: This is Bob Presley. I can make 2 that. 3 DR. WADE: Okay, so 10:00 a.m. on Monday the 4 6th we are tentatively scheduled to meet in 5 Cincinnati, at a hotel to be named, to deal 6 with the Rocky Flats site profile and SEC 7 workgroup. MR. PRESLEY: Okay, can we try to get -- if 8 9 nothing breaks or bends, try to get that hotel 10 out there at the airport? 11 DR. WADE: Yeah, we will get one at the 12 airport, certainly. 13 MR. PRESLEY: Thank you. 14 DR. WADE: Thank you. Again now, workgroup on 15 Chapman Valve SEC, that's chaired by Dr. Poston 16 -- he's not with us -- Griffon, Clawson, 17 Roessler and Gibson. John Mauro, I know you 18 spoke to Dr. Poston yesterday. Can you help us 19 in this regard? 20 DR. MAURO: Yes. In fact, Dr. Poston asked if 21 I wouldn't mind just briefing you folks on the 22 conversation we had. Bottom line is, Dr. 23 Poston would like to hold a conference call 24 working group meeting on Chapman Valve toward 25 the end of this month or early next month, the

1 date he will set soon as he's -- gets --2 opportunity to set an appropriate date with the 3 rest of the members of the working group. 4 I had indicated to Dr. Poston that by that time 5 we should have some -- we won't have our report, but we should have enough material that 6 7 I think we can get to the heart of a lot of the 8 important issues that we're concerned about 9 related to Chapman Valve. 10 We did recently receive a revised version of 11 the Chapman Valve site profile, I think 12 yesterday it came in. I did read it. We are -13 - so I think we will be in a good position to 14 have a very productive working group meeting 15 toward the end of this month or early November, 16 to be set by -- by the working group. 17 DR. WADE: Okay, so my summary is a telephone 18 call is being proposed by the working group 19 chair, end of November, early December. 20 DR. MAURO: Yes. 21 DR. WADE: Okay. And other members, you're 22 going to wait to hear from the working group 23 chair to schedule a specific time, but I see 24 that as the plan. 25 DR. LOCKEY: Did I hear end of November or

1	early December? I thought it was end of
2	October or early November.
3	DR. MAURO: I'm sorry, end of October.
4	DR. LOCKEY: Yeah.
5	DR. MAURO: This would be our first conference
6	call. We really just began work, but we've
7	done enough that I think we could have some
8	productive discussion certainly more to
9	come.
10	DR. WADE: Okay, so I misspoke, end of October,
11	early November.
12	DR. NETON: This is Jim. Could we expect to
13	see some sort of a draft report or
14	DR. MAURO: What I'd like to deliver to you is
15	a series of tables and graphs, perhaps some
16	text. I don't think it'll be something that
17	I'd like to call a draft report, but I think it
18	will be talking points.
19	DR. NETON: That's fine, just some something
20	to look at and to digest before before the
21	call.
22	DR. MAURO: Yes.
23	MR. GRIFFON: Jim, this is Mark Griffon.
24	DR. NETON: Yeah.
25	MR. GRIFFON: Good to hear your voice again, by

1 the way. 2 DR. NETON: Thanks. 3 MR. GRIFFON: I don't know -- LaVon indicated 4 in his e-mail that there was another TBD 5 forthcoming or --DR. NETON: It's been issued. I think that the 6 7 working group members and John Mauro have been 8 9 MR. GRIFFON: Yeah, I -- I have -- no, I have 10 the -- the new site profile --11 DR. NETON: That's it. 12 MR. GRIFFON: -- but you said something else 13 that was forth -- that was coming. 14 DR. NETON: Not to my knowledge. 15 MR. GRIFFON: I'm looking for the e-mail right 16 now. 17 DR. NETON: (Unintelligible) worded not quite 18 right, but --19 MR. GRIFFON: Oh, okay. 20 DR. NETON: -- we've revised -- Revision 1 of 21 the Chapman Valve site profile where some things, you know, have been bolstered up based 22 23 on comments that were made in the evaluation 24 report. We've redone the internal dosimetry 25 analysis a little bit, as John Mauro has

1 already observed. But there's nothing else 2 coming up. We -- we're working on draft dose 3 reconstructions. 4 MR. GRIFFON: Oh, okay, I see -- I guess the 5 second paragraph threw me off. He says the 6 Tech. Basis Document and sample dose 7 reconstructions --8 DR. NETON: Ah. 9 MR. GRIFFON: -- once complete, will be posted 10 on the O drive. So it is -- the TBD is the --11 DR. NETON: Right --12 MR. GRIFFON: -- revised site profile. 13 DR. NETON: -- the TBD -- I don't know if it's 14 on the O drive yet, but it should be shortly. 15 It's -- I signed it yesterday, I believe, so --MR. HINNEFELD: It's on our web site. 16 17 DR. NETON: It's on our web site already, so 18 you can get it there. We just decided to open 19 up another -- you know, on the X drive, open up 20 another folder there, so anything --21 MR. GRIFFON: Yeah. 22 DR. NETON: -- like that John puts out or 23 whatever, we can get it available to everybody. 24 MR. GRIFFON: Okay. 25 DR. WADE: Okay. Moving on to the workgroup on

1 SEC issues, paren, including the 250-day issue, 2 that's chaired by Dr. Melius with members 3 Ziemer, Roessler and Griffon. 4 DR. MELIUS: Yes, this is Jim Melius. I would 5 -- we need to schedule a working group meeting. 6 I think that's somewhat dependent on the timing 7 of a report from SC&A, and last I talked to 8 Arjun, that was expected sometime, you know, 9 second or third week in November and -- just 10 trying to pin that down 'cause I -- again, I'm 11 not sure this -- we -- it's worth meeting until 12 we have that -- that report in -- in hand and 13 give us a chance to discuss it and so forth. 14 That's -- that report does not require, I don't 15 believe, sort of NIOSH review at this point in 16 time since it's more of a conceptual, you know, 17 background on a number of issues. So once we 18 have that, we should be able to move forward. 19 I don't know, John, if you have any -- John 20 Mauro, if you have any sense of where Arjun is 21 with that. 22 DR. MAKHIJANI: Yes, I -- I'm -- I'm on the 23 call, Jim. 24 DR. MELIUS: Oh, good, Arjun. Okay. 25 DR. MAKHIJANI: Yeah, we've -- we're working

24

25

intensively on this. We -- we have a number of the documents and we're developing a conceptual approach, and an outline of the report will be ready this Friday for internal review, or early next week. And we should have a rough draft report by mid-November, as originally scheduled. You've -- you've already got the criticality piece. Now if you would -- I don't know how you want it. If you want us to kind of give you like memoranda on the pieces, or do you want to see a draft report, because there are a number of issues that we're covering --DR. ZIEMER: Well, Arjun, is rough draft -that's just an internal document at that point. That's not a draft report that you're going to issue at that point.

DR. MAKHIJANI: That's right.

**DR. ZIEMER:** Rough is just kind of the early version?

DR. MAKHIJANI: Yes, the -- the -- Dr. Ziemer, the plan is that that draft would be reviewed internally before -- before going to you, and that in the first week of December you would get the draft report, as we call it, for Board consideration. Now I'd be working with Dr.

Melius before that, as I have been, and keeping him posted -- and decide if we're going to have a meeting, and so I'll -- I'll -- I'll keep him posted as to its progress.

That's why I was suggesting maybe that I could send memoranda for consideration at that mid-November meeting and I'll know what's in the draft report internally so -- so we'll be able to talk about it then.

DR. MELIUS: Okay.

DR. MAURO: This is John Mauro. Dr. Melius, one of the steps that was taken a little earlier on was we prepared a list of documents that are in the controlled document list as part of the NTPR DTRA program. I sent that list on to Larry Elliott, who then forwarded it on to Dr. Paul Blake, who runs the -- the DTRA program. What -- I guess this is the question posed to the working group, do you know whether or not any progress has been made in obtaining those documents or if there's any problems with obtaining those documents?

DR. MELIUS: I think that's a question for NIOSH. We would have no knowledge -- this is the first time I've heard of this, so --

24

25

this.

MR. ELLIOTT: John, this is Larry Elliott. me respond to that. I have been in communication with Paul Blake at Defense Threat Reduction Agency. You know, I sent the letter, as you mentioned, requesting the four items that you are interested in. He sent me an email yesterday indicating that we would talk today about the status of those. He had no problem in providing the first three items, but the number four item was presenting some difficulty. He needed to -- as I understand it, he needed to cover some bases with their legal folks. And so I'll report -- I'll give you another update as soon as I have a conversation with Dr. Blake. We have put aside I believe a folder or are

preparing a folder on the O drive with any of the related information from your request to them that we already have in our holdings here, so just to facilitate the access and make sure we don't duplicate reproduction of information.

DR. WADE: If -- this is Lew. If I might just interject very quickly, I -- I was concerned by Dr. Melius's comment that he was not aware of

I assume, John, that this is something

1	we would discuss with the working group. NIOSH
2	is not notifying the working group.
3	DR. MELIUS: Excuse me, and just to clarify, I
4	knew that there was the re a request for
5	documents. I didn't had no knowledge of
6	sort of the the status of how it was being
7	forwarded and so forth, that's
8	DR. WADE: Okay, being sensitive to
9	communication
10	DR. MELIUS: No, no, I appreciate that, so
11	(unintelligible) necessarily expected me to
12	know that, but
13	MR. ELLIOTT: My apologies
14	DR. MELIUS: (unintelligible) asked me to
15	like answer the question.
16	MR. ELLIOTT: My apologies, but you know, I
17	knew we were going to have a conversation about
18	this today
19	DR. MELIUS: No, I
20	MR. ELLIOTT: rather than trying to belabor
21	everybody with an e-mail yesterday, not knowing
22	anything more than I already know
23	DR. WADE: Okay.
24	DR. MELIUS: It's perfectly okay, Larry,
25	believe me.

1 DR. WADE: Good. So what's the take-away 2 message from this, Dr. Melius, in terms of the 3 working group and likely getting together? 4 DR. MELIUS: Then I -- I think we just need to 5 be able to work out a date, middle of November, and somewhat -- I think we need to sort of 6 7 figure out where everybody else is in terms of 8 scheduling 'cause there's a fair amount of 9 overlap between some of the other -- with some 10 of the other groups. 11 DR. WADE: So I'll bin this as a possibility 12 during the week of the 13th, and we'll just see 13 how it works out? 14 DR. MELIUS: Yeah. 15 DR. WADE: Okay. Now to one that I think will 16 be simple, the workgroup to review SEC 17 petitions that did not qualify, chaired by Dr. 18 Lockey with members Roessler, Melius, Clawson 19 and Munn. Dr. Lockey? 20 That's -- I think -- as far as I DR. LOCKEY: 21 know, that's scheduled for November 9th in -at NIOSH in Cincinnati. 22 23 DR. ROESSLER: At NIOSH or at the airport? 24 MR. ELLIOTT: No, we'll be doing it here in the 25 offices at NIOSH.

1	MS. MUNN: We have to have access to all those
2	files.
3	DR. LOCKEY: Right. What time would that
4	start?
5	MR. ELLIOTT: What time do you want it to
6	start?
7	DR. LOCKEY: People have to fly in. Is it best
8	to start around 10:00 o'clock?
9	DR. WADE: 10:00 o'clock on the morning of the
10	9th of November at NIOSH's offices in
11	Cincinnati the workgroup will convene.
12	DR. LOCKEY: Well, what I'm asking is is
13	if people cannot fly in that morning, we could
14	start earlier, but
15	DR. MELIUS: This is Jim Melius. I'd be flying
16	in the night before.
17	DR. LOCKEY: Okay.
18	MR. CLAWSON: This is Clawson, I'd be flying in
19	the night night before.
20	DR. LOCKEY: Okay.
21	DR. WADE: Wanda?
22	MS. MUNN: I will definitely be flying in the
23	night before.
24	DR. WADE: Let's pick a gentlemanly and lady
25	time to start in the morning.

1 DR. LOCKEY: Why don't we start at 9:00 then. 2 MS. MUNN: 9:00 will be fine with me. 3 DR. WADE: 9:00 a.m. 4 DR. LOCKEY: Okay. 5 Okay, well, that's good. We've got DR. WADE: 6 a meeting scheduled for 9:00 o'clock on the 7 9th. Who can't remember that? 8 MS. MUNN: Me. 9 DR. WADE: The workgroup on Hanford site 10 profile Dr. Melius chairs, Clawson, Ziemer, 11 Poston. 12 DR. MELIUS: Yeah, where we stand with that, 13 I've been pursuing -- this is one of these site 14 profiles that's a little complicated by the 15 fact that there are several updates underway of 16 -- of different parts of it and so forth. 17 what I'm thinking -- we have a review from --18 we have a review and essentially a response 19 from -- from NIOSH, and I'm thinking the best 20 way to move forward is going to be a conference 21 call initially, just given some of the 22 scheduling issues, to try to get everybody 23 updated and then figure out a work schedule, 24 what -- what would make sense to focus on now,

what -- what issues have been -- are

25

1 essentially being dealt with with the site 2 profile updates and what the schedules are for 3 that. 4 DR. WADE: Okay. Do you want to try and set 5 that now, Dr. Melius? 6 DR. MELIUS: I think it's easier to do that --7 a conference call's easier to set up, I think. 8 DR. WADE: Okay, so you'll initiate an action 9 with your Board members and NIOSH and SC&A to 10 set up a conference call to sort of set the 11 path forward for the Hanford site profile 12 workgroup. 13 DR. MELIUS: And John Poston isn't on the call, 14 so we can't -- I don't think we should try to 15 do something today, given his schedule. 16 DR. WADE: Okay, that's good. We'll -- we'll 17 await --18 Yeah. DR. MELIUS: 19 DR. WADE: -- hearing from you. And then last 20 but certainly not least, the workgroup on 21 conflict of interest policy for the Board, 22 chaired by Lockey with Melius, Ziemer and 23 Presley. 24 DR. LOCKEY: I haven't -- I was thinking that 25 perhaps that could be done later on in the

1 I don't -- I'd ask the other members of 2 the subcommittee whether this is something that 3 has to be done right away or, with everything 4 else going on, we can delay this a little bit. 5 DR. MELIUS: This is Jim Melius. I don't see a need to -- to rush on this one and --6 7 DR. WADE: Possibly when the Board is together 8 in December this workgroup could have coffee or 9 something and -- and chart a path forward. 10 MR. PRESLEY: This is Bob Presley. I agree 11 with that. 12 DR. LOCKEY: Excellent. 13 DR. ZIEMER: Sounds good. 14 DR. LOCKEY: Okay. 15 Okay, that brings us back to, you DR. WADE: 16 know, the big week, which is 11/13, that week. 17 Right now I have four candidates for that week: 18 The subcommittee, Savannah River Site, the 250-19 day SEC issue and Nevada Test Site. At least that's my notes of all the meetings that are 20 21 possibly in play that week. We do have two 22 meetings scheduled the week before. But do we 23 want to try and figure out a way to get all of 24 that done during the week of 11/13? 25 MS. HOWELL: I'm sorry, Lew, what meetings do

1	you have scheduled the week before?
2	DR. WADE: I have Dr. Poston's meeting on the
3	petitions that didn't qualify.
4	DR. ZIEMER: No, (unintelligible).
5	DR. WADE: Then I have the Sava excuse me,
6	the Rocky Flats meeting scheduled for the 6th.
7	MS. HOWELL: Oh, I'm sorry, are we talking
8	about November 11 to 13th? I thought you were
9	talking about the Chicago meeting.
10	DR. WADE: No, I'm sorry. I'm talking about
11	the week of November 13th.
12	MS. HOWELL: Okay, thank you.
13	DR. WADE: As a candidate for four meetings.
14	MS. HOWELL: Okay.
15	DR. WADE: And you know, I don't know if if
16	someone wants to speak first, I guess you would
17	give deference to the subcommittee. Mark, do
18	you want to try and pick a day, and then we'll
19	try and organize around that?
20	MR. GRIFFON: Well, yeah, Wanda offered
21	November 16th earlier. I think that's fine
22	with me.
23	DR. WADE: Okay, so at least in terms of a
24	proposal, the subcommittee on the 16th. Then I
25	would ask subcommittee members who have other

1 responsibilities potentially during that week 2 to speak and maybe we can sort of make the --3 those other meetings butt up against the 4 subcommittee meeting. 5 MR. PRESLEY: This is Bob Presley. The NTS 6 working group, Wanda would be there on the 17th 7 -- or on the 16th. If we could get SC&A and 8 NIOSH to agree to either the 15th or the 17th, 9 that would be all right with me -- preferably 10 the 15th. 11 MS. MUNN: I'd prefer the 15th. 12 DR. WADE: Do I hear from NIOSH or SC&A? There's a proposal for the Nevada Test Site 13 14 site profile group to meet the 15th of 15 November. 16 DR. NETON: We can -- we can certainly try to 17 meet that. Again, it's going to depend on the 18 analyses that Gene Rollins is working on, but 19 we'll -- if we can't -- we could tentatively 20 schedule that. If it's not going to happen, 21 we'll get back to you. 22 DR. WADE: Okay. 23 MR. PRESLEY: I think that would be good to go 24 ahead and schedule it, give them something to 25 work to.

1	DR. NETON: Yeah.
2	MR. PRESLEY: If we make it, we make it. If
3	not, then I understand.
4	DR. WADE: Okay. Now I have left for potential
5	scheduling the Savannah River Site and the 250-
6	day SEC issue.
7	DR. MELIUS: This is Jim Melius. What about
8	the 15th for thinking certainly of Wanda
9	not Wanda, excuse me, Gen Roessler, who's on
10	the Nevada Test Site profile one and it
11	overlaps and since this also deals with
12	Nevada Test Site and there may there's some
13	sort of cross-interest whether the 15th
14	would work for the SEC issue.
15	DR. ROESSLER: But we have the Nevada Test Site
16	on the 15th.
17	DR. MELIUS: The 15th?
18	DR. ROESSLER: How about the 17th?
19	DR. WADE: Say it again, Gen?
20	DR. ROESSLER: How about the 17th or the
21	16th, if there's no
22	MR. GRIFFON: I mean do you
23	DR. ROESSLER: conflict in
24	MR. GRIFFON: Do you expect all these to be
25	all-day meetings?

1	MS. MUNN: You never can tell.
2	MR. GRIFFON: Yeah, I know, it's difficult.
3	DR. ROESSLER: Well, with Wanda let's see,
4	Wanda, you have a conflict on the 16th.
5	MS. MUNN: On when?
6	DR. ROESSLER: Let's see, we're talking about
7	the 250-day?
8	DR. MELIUS: Yeah, that's Mark
9	MS. MUNN: Yeah, I'm not on that one
10	DR. ROESSLER: You're not on that one.
11	MS. MUNN: so there's
12	DR. MELIUS: We can do the 16th.
13	DR. ROESSLER: The 16th sounds good.
14	DR. WADE: Okay.
15	MR. GRIFFON: The 16th is the day of the
16	subcommittee.
17	MS. MUNN: Yeah, and you have Mark
18	DR. ROESSLER: Oh, yeah.
19	MS. MUNN: (unintelligible) day on that one.
20	You'd probably do better with the 17th.
21	DR. WADE: Or the 14th.
22	MS. MUNN: Or the 14th.
23	DR. ROESSLER: 14th, how's that?
24	DR. MELIUS: I can't do the 14th.
25	DR. WADE: 17th?

1 DR. MELIUS: I can do the morning of the 17th. 2 DR. ZIEMER: I can do morning of the 17th. 3 DR. ROESSLER: I can do the 17th. 4 MR. GRIFFON: I can. 5 DR. WADE: Okay, so the morning of the 17th for 6 250-day, and that leaves -- with a hopeful 7 voice -- the Savannah River Site site profile 8 group. Do we want to try and --9 MR. GIBSON: Yeah, this is Mike. If -- is Joe 10 -- are you still on --11 MR. FITZGERALD: Yeah, I'm on the phone. 12 MR. GIBSON: Do you think that you guys may be 13 able -- you and NIOSH may be in a position one 14 day that week to -- to have a meeting? 15 MR. FITZGERALD: You know, certainly talking to 16 Sam about this, too, and I think you 17 characterized it very well that we have 18 identified the issues and the information that 19 we need to -- you know, more or less to close 20 specific issues out. At this point, issues 21 like the databank access and some of the other 22 items are ones where I guess we'll know better 23 once we find out whether that information can 24 be had and reviewed. If we don't get the 25 information and we don't have a chance to have

1 that review, then I'm not sure, you know, that 2 time'll be profitable. So I -- to some extent 3 I guess we're going to need to see how that 4 goes. 5 DR. ZIEMER: You want to schedule that and then -- block it off and then -- it's easier to 6 7 cancel later if you need to. 8 DR. WADE: We could put a hold on the 14th. 9 MS. MUNN: That'd be helpful for Brad 'cause 10 he's on the Nevada Test Site workgroup on the 11 15th. 12 MR. CLAWSON: This is Brad, and that's one of 13 the things I'm questioning of -- where I'm 14 sitting at right now, I've -- I've got like a 15 day in between some of those. If it would be 16 all right with Lew or whatever, that would also 17 give me the opportunity to be able to go in and 18 look into this O drive and stuff like that that 19 I haven't had ability to be able to do, and 20 then do the following meeting the next day 21 instead of just trying to hold me over and kind 22 of be there. 23 DR. WADE: That'd be fine, Brad, we would -- we 24 would consider that as time well spent. 25 DR. LOCKEY: This is Jim Lockey. I'm all right

1	the 14th in the afternoon, but in the morning
2	up to 11:00 o'clock, I'm not.
3	DR. WADE: What if we were to tentatively,
4	Mike, talk about the afternoon of the 14th?
5	MR. GIBSON: Okay.
6	DR. WADE: And then you could make the call a
7	week or two from now as to whether that's a
8	reality.
9	MR. GIBSON: Okay, I can do that.
10	DR. WADE: Good.
11	DR. LOCKEY: Okay.
12	MR. GIBSON: And who should I who can I
13	contact about the status of this databank that
14	we're trying to get access to?
15	DR. WADE: Jim Neton or someone, can you help?
16	DR. NETON: Sam Glover would be your best point
17	of contact. He's our official person as
18	DR. WADE: Can you say the name again, Jim?
19	DR. NETON: Sam Glover.
20	DR. WADE: Okay. Could you have Sam contact
21	Mike?
22	DR. NETON: Sure, I'll do that.
23	DR. WADE: Okay. So for the week of
24	MR. GIBSON: Excuse me, Lew?
25	DR. WADE: Yes, ma'am sir.

1 MR. GIBSON: Once I get this information from 2 Sam, is it appropriate for me as a Board member 3 to whoever has this data to make a request or 4 should I go through Dr. Ziemer or what's the 5 protocol for that? 6 DR. WADE: You know, Dr. Ziemer, do you have a 7 preference? 8 DR. ZIEMER: I -- I think the working group can 9 request the information that they need as part 10 of their deliberations on behalf of the Board. 11 But actually is it -- is this something that --12 that -- who identified the database to start 13 with? 14 MR. FITZGERALD: Well, Dr. Ziemer --15 DR. ZIEMER: Is this something NIOSH is trying 16 to get anyway? 17 MR. FITZGERALD: No, this is -- this is 18 something that in the site profile review SC&A 19 identified as a source of information that 20 would, you know, add to that which the site 21 profile references, and we indicated that was 22 information that would also shed light on these 23 episodic releases at Savannah River. I think 24 in our discussions it was agreed that there'd 25 be an attempt to gain access to it with the --

1 you know, certainly the -- one issue being the 2 fact that apparently DOE does not maintain that 3 database anymore and now I guess it's being 4 held by a contractor -- former contractor and I 5 think Sam was going to determine whether or not 6 this access could be arranged. And you know, 7 certainly it was a issue of the government 8 having paid for it in the first place, so there 9 should be no, you know, encumbered access to 10 it. 11 DR. ZIEMER: I quess --12 MR. FITZGERALD: I think that --13 THE COURT REPORTER: Excuse me --14 **DR. ZIEMER:** -- (unintelligible) we actually 15 may need to know or maybe -- maybe counsel can 16 help us on this, who -- who should the request 17 come from. It sounds like it either has to 18 come officially from NIOSH or from the Board, 19 and I can certainly make the request. 20 I'd want you to draft the letter and I would 21 sign it, but -- or can we do it by phone call? 22 MR. ELLIOTT: The request needs to come from 23 NIOSH, Dr. Ziemer, and we're pursuing it, so --24 DR. ZIEMER: Okay, that's --25 MR. ELLIOTT: -- (unintelligible) know exactly

1 where --2 DR. ZIEMER: -- what I thought because it'd be 3 like the DOE records. 4 MR. ELLIOTT: Yeah, we have to press this under 5 the Memorandum of Understanding --DR. ZIEMER: Right, right, that's --6 7 MR. ELLIOTT: -- that we have with DOE --8 DR. ZIEMER: -- that makes sense to me. 9 THE COURT REPORTER: Dr. Ziemer, this is Ray. 10 I'm not sure who the speaker was right before 11 you. Was that Joe Fitzgerald? 12 MR. FITZGERALD: That was me. I'm sorry, Ray. 13 Joe Fitzgerald. 14 THE COURT REPORTER: Okay. Thanks. 15 MR. ELLIOTT: I'm sorry. We'll push on this 16 and see where it's at. 17 DR. ZIEMER: Okay. 18 MR. GIBSON: And Larry, this is Mike. 19 you know, if you find any resistance -- I don't 20 know, personally I think a letter from the 21 Board to maybe some of the members of Congress would just -- you know --22 23 MR. ELLIOTT: Well, I don't know that we're 24 meeting any resistance. We certainly have the 25 Memorandum of Understanding that's served us

well up to this point, and so you know, I just don't know exactly the status. This is the first I've heard of this, so I'll -- I'll find

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

first I've heard of this, so I'll -- I'll find out where things stand.

MR. GIBSON: Okay.

DR. WADE: Thank you. Okay, so -- this is Lew. If I could just do a quick summary of what I think we've decided upon, the subcommittee is intending to meet face-to-face in Cincinnati on the 16th of November; the workgroup on the Nevada Test Site site profile scheduling to meet face-to-face in Cincinnati on the 15th of November; the workgroup on the Savannah River Site site profile tentatively scheduled to meet face-to-face in Cincinnati on the 14th at 1:00 p.m. -- 14th of November; the workgroup on the Rocky Flats site profile and SEC petition scheduled to meet face-to-face in Cincinnati on the 6th of November at 10:00 a.m.; the workgroup on Chapman Valve SEC is tentatively scheduling a call for the end of October, beginning of November, e-mail to be sent out by Dr. Poston, the workgroup chair; the workgroup on SEC issues, including the 250-day issue, scheduled to meet face-to-face in Cincinnati on

1	the 17th of November.
2	DR. ZIEMER: Do we have a time on that one yet?
3	DR. WADE: We do not.
4	DR. ROESSLER: I was wondering on that one,
5	since that's a Friday and since I'm hoping that
6	that would be at the airport and we could start
7	early.
8	DR. WADE: Okay.
9	DR. MELIUS: Is it Jim, yeah, I think Jim
10	Melius. Starting early's fine with me 'cause I
11	need to get out of there in the afternoon.
12	DR. WADE: You want to say 8:00 a.m., or 7:30?
13	DR. ROESSLER: Sure.
14	DR. MELIUS: Yeah.
15	DR. WADE: Jim, your call.
16	DR. MELIUS: 8:00 8:00 a.m.
17	DR. WADE: 8:00 a.m.?
18	DR. MELIUS: Yeah.
19	DR. ROESSLER: Thank you, Jim.
20	DR. WADE: Okay. The workgroup on the review
21	of SEC petitions that did not qualify, a face-
22	to-face meeting at NIOSH facilities in
23	Cincinnati on the 9th of November starting at
24	9:00 a.m. The workgroup on Hanford site
25	profile, a conference call to be scheduled to

1	put together a path forward. Dr. Melius will
2	send out details. And the workgroup on
3	conflict of interest policy for the Board, at a
4	time to be scheduled.
5	So I think that's important that we've gone
6	through that. Again, I can't thank you all
7	enough for your work.
8	MR. PRESLEY: Hey, Lew, this is Bob Presley.
9	DR. WADE: Sir?
10	MR. PRESLEY: We did not set a time for the NTS
11	in Cincinnati on the 15th.
12	DR. WADE: And you're about to do that.
13	MR. PRESLEY: I would like to do that at 10:00
14	o'clock in the morning, if that's all right
15	with everybody.
16	DR. ROESSLER: And would that also be at the
17	airport?
18	MR. PRESLEY: I would hope so.
19	DR. WADE: Yes, it will be.
20	DR. ROESSLER: All right.
21	DR. WADE: And then Mark, the subcommittee, do
22	you want to put a time on the 16th?
23	MR. GRIFFON: Yeah, 10:00 a.m.
24	MR. PRESLEY: What subcommittee is that, Mark?
25	DR. WADE: That is the only subcommittee, the

1	Subcommittee on Dose Reconstruction.
2	DR. ZIEMER: Dose Reconstruction.
3	MR. GRIFFON: Right.
4	THE COURT REPORTER: Dr. Wade, this is Ray. I
5	got everything on those dates except the
6	Hanford what was the date on that, or is
7	that to be announced?
8	DR. WADE: The Hanford the workgroup on the
9	Hanford site profile, a conference call to be
10	announced and shared by Dr. Melius.
11	THE COURT REPORTER: Okay. Thank you.
12	MR. GRIFFON: And we didn't we're still
13	holding off on the Chapman Valve right?
14	end of October, early November is what
15	DR. WADE: Right, a call end of October, early
16	November, Dr. Poston will notify.
17	MR. GRIFFON: All right.
18	DR. ZIEMER: Okay. I think that completes this
19	topic.
20	DISCUSSION OF SITE PROFILE REVIEW TASK
20	FOR SC&A IN FY07
21	Let's go on to the next one, which is
22	there's several parts to it. The first part is
23	discussion of site profile review tasks for
24	SC&A in February in Fiscal Year '07. You
25	may recall at our last Board meeting we we

1 set up a priority list of candidate site 2 profiles for the contractor to review. Those -3 - actually Lew -- or LaShawn sent us out a copy 4 of that -- I guess, Lew, you did -- a week or 5 so ago with the list on it as a reminder. 6 -- the two profiles that we gave SC&A a go-7 ahead on were LLNL and K-25, that's Lawrence 8 Livermore and Oak Ridge K-25. The others, in 9 order of priority, the next three were Pantex, 10 Portsmouth and Argonne West. My understanding 11 is that the contractor has the resources now to 12 proceed on a third -- third one. We authorized 13 the first two and we want to determine whether 14 the Board wishes them to proceed with Pantex or 15 whether or not the priorities have changed. 16 And Lew, do you have any additional --17 DR. WADE: No, I would --18 DR. ZIEMER: -- comments or (unintelligible) --19 DR. WADE: -- like to just clarify --20 DR. ZIEMER: -- (unintelligible) work --21 DR. WADE: -- one thing because this is not my 22 field. The first one on the list is what, John 23 Mauro? 24 DR. ZIEMER: I have Lawrence Livermore --25 MS. MUNN: Yeah.

1 DR. ZIEMER: -- is on my list. 2 DR. WADE: John, what's on your list? 3 DR. MAURO: Oh, I'm -- the -- the hierarchy, 4 based on the -- the scoring or the voting 5 weight that was given --DR. WADE: Uh-huh. 6 7 DR. MAURO: -- at the -- number one was -- on 8 the scoring was Lawrence Livermore. Number two 9 10 DR. WADE: Okay, that's fine, I just wanted to 11 make sure I didn't confuse Lawrence Livermore 12 and Los Alamos, so --13 DR. ZIEMER: Lawrence Livermore and then K-25. 14 DR. WADE: Okay, so we gave John the go-ahead 15 on two. 16 DR. MAURO: Right. 17 DR. WADE: When I talked to John recently, 18 along with David Staudt, John tells us that 19 he's in a position to begin work on the third. 20 We don't want to delay the contractor and their 21 work, so I thought we might take this 22 opportunity to give John the go-ahead on a 23 third. The third on our voting was Pantex. 24 DR. ZIEMER: And so, Board members, the 25 question is do you wish to have -- authorize

1	the contractor to proceed with Pantex, or has
2	our priorities changed?
3	MS. MUNN: This is Wanda. I still feel that
4	Pantex is different enough from the other sites
5	that we've looked at so far that it's logical
6	to keep it in its current position. I'd like
7	to see them move forward on that.
8	MR. CLAWSON: This is Brad. I see no problem
9	with proceeding with Pantex. I think it
10	it's valuable that we get into that one fairly
11	soon.
12	MR. PRESLEY: This is Bob Presley. I agree.
13	DR. ZIEMER: Are there any Board members who
14	feel we should change?
15	(No responses)
16	If not, can I take it without objection that
17	we'll authorize the contractor to proceed with
18	the review of the Pantex site profile?
19	(No responses)
20	There appears to be no objection.
21	DR. WADE: Thank you.
22	DR. ZIEMER: So authorized.
23	DR. WADE: Thank you.
24	NEED FOR NEW WORKING GROUPS
24	(I.E. PROCEDURES REVIEW)
25	DR. ZIEMER: Okay. Need for new working

groups. You know that we -- we did authorize the contractor to proceed with reviewing some new procedures. As they progress in that and the findings are developed, we will need a working group to review that -- those, so -- and John Mauro, can you tell us where we are on that task?

DR. MAURO: Yeah, on the new set of procedures
-- if you recall, where we stand is you folks
have identified 15 --

DR. ZIEMER: Uh-huh.

DR. MAURO: -- for us to begin with. We have -- our contract calls for 30, so you -- we -- we have started work on allocation of the first 15. In fact the most important one, dealing with construction -- OTIB-52 -- work has begun. Arjun is -- is leading that up. However the others, work has not proceeded very far and -- and we are again -- we are expecting at some point in the process it wouldn't be a bad idea if we have some direction by -- by December for the other 15 so we could have the full cadre of 30 identified.

By the way, as an aside, if you recall, you also identified that there were seven that --

procedures that have already been effectively reviewed as part of the site profile process, so in effect our plan is to deliver a report that covers a total of 37 procedures in the deliverable that will come out of this proc-product -- project. We -- we have certainly adequate work right now to move forward with the 15. There's no urgency right now for the -- the Board to identify the next set of 15.

DR. ZIEMER: Yeah.

DR. WADE: Is there -- is there a -- would it would it suit you, John, to have a workgroup
identified today, or might that wait until
December?

DR. MAURO: I think it would be good today.

I'll tell you why. We are moving forward right now with one of the most important OTIBs, 52, dealing with construction. And that's going to turn out to be a little bit more of an involved review than let's say the others where collaboration and keeping the working group apprised of developments -- for example, we're hoping to bring aboard some specialists in construction working through Knut, who had expressed a great deal of interest in that and

-- and it wouldn't be a bad idea to move forward with those activities in collaboration with a working group. So I guess -- if I had my 'druthers, it would be very desirable to have a working group there as we start to move into the -- specifically this one particular procedure.

DR. WADE: Okay, fine. And just for the record, the reason we sort of face this -- this mini-vacuum is that in the past the subcommittee, as it was previously constituted, dealt with procedures, and as it is being reconstituted deals only with dose reconstruction.

DR. ZIEMER: Yeah.

DR. WADE: So Paul, it's your pleasure.

DR. ZIEMER: Yeah. Well, it sounds like it'd be useful to go ahead and have the committee work -- or the workgroup in place so that when needed they'd be -- be ready to go into operation. I think I'd like to first give folks the opportunity, if they're interested in this particular workgroup, to -- to volunteer. So who would like to be part of this workgroup on procedures review, recognizing that there's

1	no immediate work on it. Work would probably
2	begin after our next meeting and into next year
3	sometime.
4	MR. GRIFFON: Paul, I'm I'm interested. I'd
5	rather not chair. I've got a lot of
6	DR. ZIEMER: Mark Griffon.
7	MR. GRIFFON: prongs in the fire.
8	DR. ZIEMER: Sure.
9	MS. MUNN: This is Wanda
10	MR. GIBSON: This is Mike, I volunteer for that
11	that, but I'd rather not chair it, either
12	DR. ZIEMER: Gibson, who else?
13	MS. MUNN: Yeah. This is Wanda, I'm not wild
14	about chairing it, either.
15	DR. WADE: But you didn't say you wouldn't.
16	MS. MUNN: No, I didn't say I wouldn't.
17	DR. ZIEMER: Who else indicated an interest?
18	All right, Griffon, Gibson and Munn.
19	(No responses)
20	Okay. Well, I guess the Chair is going to put
21	himself on that then, that'll give us four.
22	DR. WADE: Okay.
23	MR. GRIFFON: I mean there's one other thing is
24	that what John just said I mean there may
25	be a good reason for breaking off that one

1	procedure on construction workers to just have
2	a separate construction worker workgroup, you
3	know, looking at
4	DR. ZIEMER: Well, and in fact
5	MR. GRIFFON: You know, if there's
6	(unintelligible)
7	DR. ZIEMER: this this workgroup
8	MR. GRIFFON: (unintelligible) almost like a
9	site profile.
10	DR. ZIEMER: this workgroup may end up
11	concentrating that on that as their initial
12	task 'cause that's probably going to be one of
13	the things. If we need a separate workgroup,
14	we will, but
15	MR. GRIFFON: Okay.
16	DR. ZIEMER: at least this one is there to -
17	_
18	MR. GRIFFON: Yeah.
19	DR. ZIEMER: start that. Anyone else
20	interested in this?
21	MR. PRESLEY: This is Bob Presley. I would be
22	interested in working on that, but not chairing
23	it, also.
24	DR. ZIEMER: Okay. Let me I'm going to put
25	you down as an alternate, Robert, so we have

1 four --2 MR. PRESLEY: That'd be fine. 3 DR. ZIEMER: -- plus an alternate, and I will 4 serve as chairman pro tem. 5 MS. MUNN: Good. 6 DR. WADE: Do you feel you have the experience, 7 Paul, to do that? 8 MS. MUNN: He probably (unintelligible) --DR. ZIEMER: Well, I'll work on it. Okay, that 9 10 gives us at least a group to go forward. 11 DR. WADE: Okay, thank you very much. 12 appreciate that. 13 DR. ZIEMER: And it may be -- Poston isn't on 14 the line, and it may be that Poston will agree 15 to -- to participate in that. I'll move out if 16 he's -- would be interested. 17 DR. WADE: And remember that in -- in the letter we received from -- our friends, this 18 19 issue of the Board addressing the construction 20 workers was raised, so I think this action 21 would be found consistent with that. DR. ZIEMER: Yeah, right. Okay, that takes 22 23 care of that workgroup. 24 DR. MELIUS: This is Jim Melius. I need to 25 sign off and go to another meeting, so --

1 DR. WADE: Thank you, Jim.

## DR. MELIUS: -- thank everybody. DISCUSSION OF WORKING GROUP & SUBCOMMITTEE

## MEETING DURING THE DECEMBER FACE-TO-FACE MEETING

DR. ZIEMER: I think we're basically done.

We're -- we're really -- need to determine

which of these groups are going to meet before

our meeting in December, also. That is on the

morning of our December meeting.

DR. WADE: I mean historically we always reserve the morning of the first day for the subcommittee. We could continue to do that. It could be a time for other workgroups, but there's such an overlap between workgroups and subcommittee it's hard to imagine that more than a couple could meet. I just didn't know -

DR. ZIEMER: Yeah, what -- what I think I'm going to suggest, Lew, in that regard is that the various workgroups that are going to be meeting in the next month or so, if any of them need follow-up meetings in -- at the front end of our meeting in -- in December, perhaps they could let you know and we can try to schedule them. It may be that they'd have -- some of them would have to be sequential rather than

1	simultaneous because of overlap of membership.
2	DR. WADE: Fine. Mark, do you want me to hold
3	the morning of the first day for subcommittee
4	meeting possibly?
5	MR. GRIFFON: Possibly, yeah. Yeah, but I can
6	also see it, if desired, to meet with the Rocky
7	Flats
8	DR. WADE: Okay.
9	MR. GRIFFON: it might be
10	DR. WADE: So the subcommittee will have no
11	no preference to that morning at this point.
12	Right now I'll say we'll start the Board
13	meeting 1:00 o'clock on the first day
14	DR. ZIEMER: And we may
15	DR. WADE: and we'll use the morning as
16	appropriate.
17	DR. ZIEMER: at least one workgroup planned
18	to meet, though.
19	DR. WADE: Okay.
20	DR. ZIEMER: Whichever is most urgent,
21	probably.
22	DR. WADE: Okay.
23	DR. ZIEMER: Okay. Are there any other items
24	of business that need to come before us today?
25	MR. GIBSON: Paul, this is Mike. I've got a

1 question. 2 DR. ZIEMER: Yeah. 3 MR. GIBSON: If memory serves me right, 4 Battelle's contract has -- period has ended. 5 Do they have a deliverable for NIOSH and is 6 that available to the Board? 7 DR. ZIEMER: Battelle's -- the dose 8 reconstructions that they were doing? 9 MR. GIBSON: Yes. 10 MR. ELLIOTT: Mike, this is Larry Elliott. Let 11 me answer your question if I can. Battelle has 12 been awarded a contract mod for a no-cost 13 extension. I believe it goes through May of 14 2007, and that will consume the remainder of 15 funds that they have not expended to this date, 16 as well as we have specified exactly what we 17 want them to accomplish with the remaining 18 funds and the time frame that has been extended 19 So we're making those contract 20 modifications happen at -- now, at this time. 21 DR. ZIEMER: Okay? 22 MR. PRESLEY: Hey, Paul, this is Bob Presley. 23 DR. ZIEMER: Yeah. MR. PRESLEY: Back about four or five years ago 24 25 the Board asked NIOSH if there was any way that

1 periodically, quarterly, whatever, we could get 2 a summary of what we had been paid out in the 3 way of wages and also what we have been paid 4 out in the way of reimbursement. I would like 5 to know if that can be talked about at the next Board. I think that that's something that 6 7 needs to come up and we need to readdress, 8 because --9 DR. ZIEMER: You're asking for individual mem--10 information that individual members could have 11 on what they've been paid? 12 MR. PRESLEY: That's correct. I want a paper 13 trail. DR. ZIEMER: Now I get, every two weeks, from 14 15 this federal pay thing --16 MS. MUNN: Mil pay thing. 17 DR. ZIEMER: What is it called? 18 MS. MUNN: I think it's mil pay, if I remember 19 correctly. 20 DR. ZIEMER: Which gives the earnings for that 21 period and the earnings to date for the year. 22 Are you not getting something like that? 23 MR. PRESLEY: I've not been able to get on that 24 web site. The other thing is, we don't know --25 all you do is you just get a -- an amount that

1 shows up in your checking account ever so often 2 after a -- after a -- a meeting or something. 3 I would like to see some type of a -- of a --4 of an expense report or something like this for 5 what we've been paid for and what we've turned 6 in. 7 DR. WADE: I will see that it's on the agenda 8 to discuss, Robert. 9 MR. PRESLEY: Lew, I appreciate that very much. 10 DR. LOCKEY: Lew, I agree with that because for 11 tax purposes, it's going to be a problem at the 12 end of the year figuring out expenses versus 13 everything else. 14 DR. WADE: I will just have somebody come -- I 15 know there are lots of issues that each of you 16 have and I -- I'll have somebody come and face 17 you and -- and hear the concerns and tell you 18 the way it should be and you can tell them the 19 way it is. MR. PRESLEY: Okay, Lew, I would appreciate 20 21 that very much. 22 MS. MUNN: As long as --23 DR. WADE: It would be my pleasure. 24 MS. MUNN: As long as we're discussing pay 25 issues, there has -- has there been any success

1	at all in getting the State of Georgia to agree
2	to stop withholding state withholding tax for
3	those of us who don't live or even travel
4	through Georgia?
5	DR. WADE: It is being worked on. I cannot
6	report success at this point, but I can report
7	diligent effort. And hopefully by December
8	I'll have something to more positively to
9	tell you.
10	MS. MUNN: If there's something that we should
11	be doing as individuals, I'd certainly like to
12	know what that is.
13	MR. CLAWSON: Hey, Wanda, this is Brad. If you
14	get onto that that site, you can actually
15	change your
16	MS. MUNN: I have done that three times.
17	MR. CLAWSON: Have you? Me, too, so
18	MS. MUNN: With no success.
19	DR. LOCKEY: What is what is that site?
20	MS. MUNN: It is mypay.dsas.mil/mypay that's
21	m-y-p-a-y <u>.asex</u> .
22	DR. LOCKEY: asex?
23	MS. MUNN: Uh-huh.
24	(Multiple members spoke simultaneously.)
25	DR. WADE: (Unintelligible) to everyone as

1 well, would you mind? 2 MS. MUNN: Yeah, I could --3 MR. PRESLEY: Hey, Wanda --4 MS. MUNN: Yes. 5 MR. PRESLEY: -- you might want to check in. 6 They have even been turning in my per diem and 7 my travel and everything as income. 8 MS. MUNN: Yeah, well, I know -- I know the 9 State of Georgia has a couple of thousand 10 dollars of my monies that they've been 11 withholding and I'd -- I'd like it to go to the 12 feds, if it's going to be withheld. DR. ZIEMER: Well, we -- we need someone there 13 14 at the meeting that can try to address these 15 issues probably. 16 DR. WADE: Right, I'll try and get someone. 17 DR. ZIEMER: And maybe someone who can explain why our Board's per diem -- or our Board's 18 19 consulting rate is different than the DTRA 20 Board, or at least I'm told it is. Do you know 21 22 DR. ROESSLER: I've heard that, too. 23 MR. PRESLEY: It is. 24 MS. MUNN: Oh, it's not just the DTRA board. 25 We're the cheapest date in town, guys.

1	DR. ZIEMER: Well
2	MS. MUNN: That's through the waste board and
3	several other boards.
4	MR. PRESLEY: I think it's high time that we
5	have somebody come talk to us about these
6	things.
7	DR. WADE: We'll try and get someone.
8	DR. LOCKEY: I agree.
9	DR. ZIEMER: Okay, any anything else for the
10	good of the order?
11	MR. CLAWSON: This is Brad. I just wanted to
12	make sure so we're planning for December to
13	meet as a full Board in Chicago?
14	DR. ZIEMER: Correct.
15	MR. CLAWSON: Okay. I just I just got the -
16	- the one from Lew there and I wanted to make
17	sure that we're the dates were correct and
18	that's where we were going to go.
19	DR. WADE: That's correct.
20	MR. PRESLEY: Do we know yet what hotel we're
21	going to be in, or what part of town?
22	DR. WADE: I do not. I will let you know as
23	soon as I find out.
24	DR. ZIEMER: If you're able to get something
25	near O'Hare, it might be good. I don't know if

1 members will really want to be downtown, but --2 DR. WADE: No, we won't go downtown, I'll try 3 to --4 DR. ZIEMER: -- I certainly don't. 5 MR. PRESLEY: Wonderful. DR. WADE: I'll try near O'Hare. 6 7 MR. PRESLEY: That's good. 8 MR. ELLIOTT: Lew, this is Larry Elliott. It -9 - this is in res-- this meeting is being held 10 in Illinois for the Blockson Chemical SEC 11 petition --12 MS. MUNN: Right. 13 MR. ELLIOTT: -- deliberation, and that's in 14 Joliet, and I -- I assume you're all aware that 15 Joliet's about 60 miles southwest of Chicago. 16 MS. MUNN: Yeah. 17 MR. ELLIOTT: So I just offer that for your 18 consideration. 19 DR. ZIEMER: If you got to O'Hare, the drive to 20 Joliet is faster than the drive downtown. 21 MR. ELLIOTT: It probably is. But just so you 22 know, as typically and traditionally, we will 23 notify claimants in the -- in the area. But to 24 hold it in Chicago, we may see a --25 DR. ZIEMER: But there are some good conference

1	centers, for example, near Naperville, which is
2	quite accessible to Joliet and which is much
3	easier to get to than than Chicago itself
4	from the airport.
5	DR. WADE: Okay, so I will aim for Joliet or
6	Naperville or
7	DR. ZIEMER: Probably probably not Joliet
8	itself.
9	MR. PRESLEY: Well, this is Bob Presley.
10	Really think about going to Denver in February.
11	The weather the weather could be absolutely
12	terrible. Part of us might get in, part of us
13	might not get out. Really have a hard look at
14	February's Board meeting. I mean it's
15	there's too many places that we need to go.
16	DR. WADE: Okay, I understand.
17	DR. ZIEMER: Okay. Anything else?
18	(No responses)
19	If not, I'll declare the meeting adjourned.
20	Thank you very much.
21	DR. WADE: Thank you all.
22	(Whereupon, an adjournment was taken at 12:05
23	p.m.)
24	
25	

CERTIFICATE OF COURT REPORTER

## STATE OF GEORGIA COUNTY OF FULTON

I, Steven Ray Green, Certified Merit Court Reporter, do hereby certify that I reported the above and foregoing on the day of October 18, 2006; and it is a true and accurate transcript of the testimony captioned herein.

I further certify that I am neither kin nor counsel to any of the parties herein, nor have any interest in the cause named herein.

WITNESS my hand and official seal this the 4th day of November, 2006.

\_\_\_\_\_

STEVEN RAY GREEN, CCR

CERTIFIED MERIT COURT REPORTER

CERTIFICATE NUMBER: A-2102